1	"Identification of potential high-risk clones of Carbapenem-Resistant
2	Pseudomonas aeruginosa co-producing, KPC-2, VIM-2 and OXA-74 from tertiary
3	hospitals in Metro Manila, Philippines"
4	Sherill Tesalona ^{a,b} #, Miguel Francisco Abulencia ^c , Maria Ruth Pineda-Cortel ^{a,b,d} , Sylvia A Sapula ^e ,
5	Henrietta Venter ^e , and Evelina Lagamayo ^{f,g,h}
6	
7	^a The Graduate School, University of Santo Tomas, Manila, Philippines
8	^b Department of Medical Technology, Faculty of Pharmacy, University of Santo Tomas, Manila 1015,
9	Philippines
10	^c Molecular Biology Laboratory, Research Institute for Tropical Medicine, Alabang, Muntinlupa City 1781,
11	Philippines
12	^d Research Center for the Natural and Applied Sciences, University of Santo Tomas, Manila 1015,
13	Philippines
14	^e Health and Biomedical Innovation, Clinical Health Sciences, University of South Australia, Adelaide 5000,
15	Australia.
16	^f Institute of Pathology, St. Luke's Medical Center, Cathedral Heights, Quezon City 1112, Philippines
17	^g Institute of Pathology, Chinese General Hospital and Medical Center, Manila 1014, Philippines
18	^h Department of Clinical Pathology, University of Santo Tomas Hospital, Manila 1015, Philippines
19	
20	Running Head: Genomic analysis of Pseudomonas aeruginosa strains collected in Manila,
21	Philippines
22	
23	#Address correspondence to Sherill Tesalona, sdtesalona@ust.edu.ph.

24 ABSTRACT

25 Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is an opportunistic human pathogen and 26 a global public health concern due to the limited treatment options available for infections by this 27 pathogen. Identification of antimicrobial resistance (AMR) determinants at an early phase is 28 crucial to administer the appropriate treatment in a timely manner, thereby alleviating the 29 transmission and enhancing the outcomes of patients infected with these pathogens. This study investigated the whole genome sequence (WGS) of 35 CRPA isolates obtained from three 30 31 hospitals in Metro Manila, Philippines, collected from August 2022 to January 2023. The 32 investigation revealed that a high proportion of isolates obtained from Hospital B and C contained 33 acquired AMR determinants. The traditional multilocus sequence type (MLST) analysis using 34 Pasteur nomenclature in the PubMLST database revealed six different known sequence types 35 (STs), namely ST111, ST175, ST1822, ST357, ST3753 and ST389 and the highest number of unknown STs (27 singletons). Moreover, to delineate the unknown STs identified, the Pasteur 36 37 nomenclature in the Pathogenwatch database was used, which led to the identification of novel 38 STs. Notably, a novel ST4b1c was found to co-produce the metallo-beta-lactamase (MBL) NDM-7, extended-spectrum beta-lactamases (ESBLs) CTX-M-15 and TEM-2, as well as class D OXA-395. 39 40 Furthermore, potential high-risk clones represented by ST389 and novel STs (ST95c6, STf555, and STab6a) were identified, all of which co-produced carbapenemases KPC-2, VIM-2, and OXA-74. 41 This study represents the first report in the Philippines on the co-production of ESBL KPC-2, MBL 42 VIM-2 and Class D OXA-74 hosted by potential high-risk clones and novel STs. It underscores the 43 need for continuous surveillance and monitoring of other problematic strains. 44

45

Keywords: multidrug resistance, antimicrobial resistance, whole genome sequence, sequence
type, carbapenem antibiotic, carbapenemase

48 **INTRODUCTION**

49 Pseudomonas aeruginosa (P. aeruginosa) is one of the six leading pathogens for deaths associated with antimicrobial resistance (AMR) and is responsible for an estimated 929,000 50 deaths attributable to AMR and 3.57 million deaths associated with AMR in 2019 (Murray et al., 51 2022). P. aeruginosa is an opportunistic pathogen (Arzanlou et al., 2017; Raman et al., 2018; Sid 52 Ahmed et al., 2022) that causes serious infections in healthcare environments and among 53 individuals with impaired immune systems (Amsalu et al., 2020; Bogiel et al., 2021). P. aeruginosa 54 55 that is resistant to carbapenem antibiotics, is an emerging and urgent threat (Murray et al., 2022; Willyard, 2017). In 2017, the World Health Organization (WHO) categorized carbapenem-56 resistant P. aeruginosa (CRPA) as "critical," necessitating the urgent development of new 57 antibiotics (Tacconelli et al., 2018). The emergence and dissemination of the CRPA and the 58 59 reported "high-risk" clones that are frequently resistant to multiple antibiotics pose an urgent 60 threat to the general welfare of the global population and represents a global risk to public health (Hu et al., 2021; Kocsis et al., 2021; Oliver et al., 2015). The main mechanisms by which P. 61 62 aeruginosa can develop resistance to carbapenems are the following: the production of enzymes that can degrade carbapenem antibiotics, such as the carbapenemases (Amsalu et al., 2021); 63 overexpression of drug efflux pumps, like those in the resistance-nodulation-division (RND) family, 64 65 which help the cell to export carbapenems (Amsalu et al., 2020); and decreased outer membrane permeability through the downregulation or loss of OprD porins required for carbapenem entry 66 (Li et al., 2012; Shariati et al., 2018; Shu et al., 2017). Carbapenemases are enzymes that can 67 hydrolyze carbapenem antibiotics, rendering them ineffective (Amsalu et al., 2021; Queenan & 68 69 Bush, 2007). Carbapenemases are classified into two families: serine and metallo-beta-lactamases

(MBLs) (Sahuquillo-Arce, 2015). Serine beta-lactamases such as class A (e.g. KPC, PER) and class 70 71 D beta-lactamases (e.g. OXA-10, OXA-74) that require a serine residue at the active site (Bush & Jacoby, 2010). MBLs are Ambler class B enzymes that require one or two zinc ions for catalytic 72 73 activity, such as New Delhi metallo-beta-lactamases (NDM) and Verona-Integron metallo-beta-74 lactamases (VIM) (Bush & Jacoby, 2010). MBLs, unlike serine beta-lactamases, are not inhibited 75 by typical therapeutic inhibitors like clavulanic acid, tazobactam, or sulbactam (Sawa et al., 2020). Their propensity to efficiently hydrolyze practically all carbapenems (Pedroso et al., 2020; Zhao & 76 77 Hu, 2015) and rapid proliferation compromise existing therapeutic choices (Amsalu et al., 2021). 78 The acquisition of carbapenemases is of great concern as they can hydrolyze most beta-lactam antibiotics (Schäfer et al., 2019) and are often encoded by genes carried on mobile genetic 79 80 elements such as plasmid, transposon, and insertion sequences, facilitating their transfer to other bacterial species (Yoon & Jeong, 2021). 81

82 Carbapenemase production is a rare cause of carbapenem resistance in *P. aeruginosa* 83 isolates in the United States (Karlowsky et al., 2018; Reyes et al., 2023) but is identified in more than 20% of other regions (Gajdács, 2020; Gill et al., 2021; Karlowsky et al., 2018). Studies have 84 reported a prevalence of 18.9% of CRPA in the Asia-Pacific region and a high incidence of 85 carbapenemase-producing P. aeruginosa in China and Indonesia (Arowolo et al., 2023; Wang et 86 87 al., 2021). Furthermore, according to CDC and ECDC reports, the MBL-producing P. aeruginosa 88 increased from 4.0% (2021) to 9.0% (2022), and the most commonly identified carbapenemases are VIM, KPC and IMP (CDC, 2019; Nordmann & Poirel, 2019; Reyes et al., 2023; Tacconelli et al., 89 90 2017). Several countries in Southeast Asia, including Bangladesh, India, Indonesia, Nepal, Sri Lanka, and Thailand, have observed a worrying trend of increasing drug resistance, while the 91

Philippines was not mentioned in the report (Sihombing et al., 2023). However, a study by Argimon et al., 2020 revealed that in the Philippines, resistance rates to critical pathogenantibiotic combinations, such as carbapenem-resistant organisms, have steadily increased over the past decade (Argimón et al., 2020). In the annual report of the Antimicrobial Resistance Surveillance Reference Laboratory (ARSRL) of the Philippines, a significant decrease in the resistance rate of *P. aeruginosa* to meropenem (p = 0.0000) from 2021 to 2022 was observed; however, imipenem was never mentioned (Department of Health - RITM, 2022).

99 In spite of the high incidence of CRPA and the critical need for new antimicrobials against 100 this pathogen, there is a scarcity of research regarding the genetic and molecular epidemiological attributes of CRPA strains in the Philippines. Given that AMR and CRPA, in particular, is a global 101 102 concern that significantly impact our health and economy, a better understanding of the molecular 103 epidemiology of this critical pathogen is needed to tailor treatments and mitigate the risk for 104 dissemination. Hence, this study reports on the surveillance of CRPA from three hospitals in the Philippines over a six-month period. Whole genome sequencing (WGS) was used to identify 105 106 resistance genes and to provide insight into the molecular epidemiologic landscape of P. 107 aeruginosa.

108 **RESULTS**

Sample information A total of 35 CRPA isolates were obtained from a cohort of patients aged 14 to 93 years, 57.0% of which are male. The distribution of CRPA isolates across hospital wards and specimen types was are as follows: 46.0% (n = 16/35) were obtained from the intensive care units (ICU), followed by the medicine department for adults 37.1% (n = 13/35) And pediatrics 2.9% (n = 1/35). The obstetrics and gynecology, and surgery departments contributed 9.0% (n = 114 3/35) and 6.0% (n = 2/35) of the CRPA isolates analyzed. The 35 CRPA isolates that were 115 investigated were obtained from respiratory specimens (endotracheal aspirate, sputum, and 116 bronchoalveolar lavage), blood, gastric aspirate, wound tissue, ascitic fluid, bone aspirate and 117 catheter drain with the following distributions: 68.0% (n = 24), 11.0% (n = 4) 9.0% (n = 3), 2.9% (n 118 = 1), 2.9% (n = 1), 2.9% (n = 1) and 2.9% (n = 1), respectively (Supplemental File 1).

119 120

The phenotypic AMR profile reveals high proportion of resistance to ciprofloxacin, ceftazidime, and cefepime

121 The phenotypic analysis exhibited the following incidence of resistance: ceftazidime (CAZ) 122 60.0% (n = 21/35), cefepime (FEP) 57.1% (n = 20/35), piperacillin-tazobactam (TZP) 48.6% (n = 17/35), amikacin (AMK) 20.0% (n = 7/35), ciprofloxacin (CIP) 62.9% (n = 22/35), and aztreonam 123 (ATM) 38.1% (n = 8/21). Resistance to CIP, CAZ, and FEP was observed from a large proportion of 124 125 CRPA isolates, 62.9%, 60.0%, and 57.1%, respectively (Table 1). Following the CLSI breakpoints, 126 there were CRPA isolates obtained from Hospital C that showed resistance to Ceftazidimeavibactam (CZA) 63.6%, (n = 7/11), and colistin (COL) 25.0%, (n = 5/20). Interestingly, according to 127 128 EUCAST, only one (n = 1/20) of the isolates would be COL resistant following the MIC breakpoint of >4 mg/L. However, not all isolates have been subjected to antimicrobial susceptibility test 129 against CZA and COL following the Clinical and Laboratory Standards Institute, 32nd ed, 2022 (CLSI) 130 131 guidelines (CLSI, 2022) and the institutional (isolation site) protocol. Whereas all the CRPA isolates 132 obtained and investigated are 100.0% IPM resistant, only 82.9% (n=29/35) are tested MEMresistant (Table 1 and 2). The phenotypic AMR is shown in Supplemental File 2. 133

Table 1: MIC distribution for 35 CRPA isolates obtained from three tertiary hospitals in Metro Manila, from August 2022 to Januar	у
2023 following the CLS1, 2022 guidelines.	

	No. of is	olates at a	an MIC	(mg/L) (of:								
Antibiotics	0.125	0.250	0.5	1	2	4	8	16	32	64	128	Breakpoint(s) ^b	R (%)
IPM ^d , ^e								35 ^{+, a}				≤2/≥8	100.0
MEM ^d		1 *				5	3 +, a	1, 25 ^{+, a}				≤2/≥8	82.9
CAZ ^d						11		3, 7+	1 ^{+, a}	13 ^{+, a}		≤8/≥32	60.0
FEP ^d				5 *	3		3	4,6+	1 ^a	13 ^{+, a}		≤8/≥32	57.1
CZA ^e					1	3	7*					(≤8/4)/(≥16/4)	63.6
TZP ^d						4 *	1	4	9	12 +	5 ^{+, a}	(≤16/4)/(≥128/4)	48.6
COL ^e				9 *	6	4 ^a		1 ^{+, a}				≤2/≥4	25.0
CIP ^d	1*	4*	6*	2	10 ^{+, a}	11 ^{+, a}				1 ^{+, a}		≤0.5/≥2	62.9
AMK ^d					10 *	3	9 *	3	3	7 ^{+, a}		≤16/≥64	20.0
	No. of is	olates at :	zone dia	ameter (mm) ⁵of:								
	12	13	14	15	16	17	18	19	20	21	22	Breakpoint(s) ^c	_
ATM ^f	1 ^a			7 ^a	1	1			4		7	≥22/≤15	38.1

CRPA, carbapenem-resistant *P. aeruginosa;* AMR, Antimicrobial resistant; IPM, imipenem; MEM, meropenem; CAZ, ceftazidime; FEP, cefepime; CZA, ceftazidime-avibactam; TZP, piperacillin-tazobactam; AMK, amikacin; CIP, ciprofloxacin; COL, colistin; and ATM, aztreonam.

^a indicates data for resistant strains as per CLSI 2022; * MIC ≤ the indicated value; + MIC > the indicated value; ^b Breakpoint concentrations - expressed as "susceptibility (mg/L)/resistance (mg/L)" and ^c Breakpoint concentrations - expressed as "zone of inhibition in mm" - are presented according to CLSI 2022; ^d MIC detected using Vitek®2 system (bioMérieux); ^e MIC detected using Thermo Scientific[™] Sensititre[™]; and ^f MIC detected using Kirby Bauer technique.

Differences in the prevalence rate and level of resistance to third (CAZ) and fourthgeneration cephalosporin (FEP), and fluoroquinolone (CIP) among the three hospitals

The 35 CRPA isolates investigated are relatively not equally distributed among the three 137 138 isolation sites: (Hospital A, n = 8/35), Hospital B, n = 16/35, and Hospital C, n = 11/35), 22.9%, 139 45.7%, and 31.4%, respectively. Hospital B has the highest number of CRPA isolates investigated in this study. Analysis revealed that 62.5 % (n =10/16) of CRPA isolates obtained from Hospital B 140 showed resistance to CAZ, FEP, and CIP, while 72.7% (n = 8/11) of CRPA isolates obtained from 141 142 Hospital C showed resistance to both CAZ and FEP and a high proportion of CIP resistance, 90.9% (n = 10/11) (FIG 1A). Moreover, low proportion of resistance against CAZ, FEP, and CIP was 143 observed in CRPA isolates obtained from Hospital A. Only 37.5% (n = 3/8) CRPA isolates from 144 145 Hospital A showed resistance to the third-generation cephalosporin CAZ, and 25.0% (n = 2/8) showed resistance against fourth-generation cephalosporin FEP, and fluoroquinolone (CIP). The 146 147 incidence rate and resistance level against CZA and COL cannot be compared from the three 148 isolation sites because the institutions have different protocols for testing multidrug-resistant organisms (MDROs) against these antibiotics. Of the three isolation sites, only Hospital C has 149 150 automatically included testing CZA and COL against MDROs and reported following the cascade reporting rules and upon the physician's request. Out of the 11 isolates tested from Hospital C, 151 152 63.6% (n = 7/11) expressed resistance against CZA (MIC >8 mg/L) and 18.2% (n = 2/11) expressed 153 resistance against COL (MIC \geq 4 mg/L) (FIG 1A, Tables 1 and 2 and Supplemental File 2).

						MIC (mg/L	-)				Zone Diameter Breakpoints (mm)
		IPM ^a	MEM ^a	CAZª	FEP ^a	CZA⁵	TZP ^a	AMK ª	CIPª	COL⁵	ATM°
Isolate	Specimen Type	≥8	≥8	≥32	≥32	≥16	≥128	≥64	≥2	≥4	≤15
P01T	BAL	>16	>16	16	16	N/T	32	<2	1	>16	15
P02T	Blood	>16	>16	4	2	N/T	16	<2	2	N/T	N /T
P03T	ETA	>16	4	>32	8	N/T	32	<2	<0.25	N/T	20
P04T	Blood	>16	>16	4	2	N/T	16	<2	2	N/T	20
P05T	BAL	>16	>16	16	16	N/T	32	16	1	N/T	15
P06T	BA	>16	>16	>64	>64	N/T	>64	<2	<0.25	N/T	12
P07T	Sputum	>16	>16	>64	>64	N/T	>64	<2	0.5	N/T	15
P08T	ETA	>16	>16	4	8	N/T	32	<2	<0.25	N/T	15
P01L	ETA	>16	>8	4	≤1	N/T	32	8	0.5	N/T	16
P02L	Blood	>16	4	4	≤1	N/T	<4	<8	0.5	N/T	22
P03L	Blood	>16	>8	>64	>64	N/T	32	32	>4	N/T	22
P04L	Sputum	>16	>8	>64	>64	N/T	>128	4	<0.125	N/T	22
P05L	ETA	>16	>16	>64	>64	N/T	>64	>64	>64	N/T	15
P06L	Wound Tissue	>16	>16	>64	>64	N/T	32	<2	>4	4	N/T
P07L	ETA	>16	4	4	≤1	N/T	<4	4	>4	N/T	15
P08L	Catheter Drain	>16	4	4	≤1	N/T	<4	4	<0.5	N/T	22
P09L	Gastric Aspirate	>16	≤ 0.25	4	≤1	N/T	<4	<2	<0.5	2	22
P10L	Gastric Aspirate	>16	4	4	2	N/T	32	<2	<0.5	2	N/T
P11L	ETA	>16	>16	>64	>64	N/T	>128	>64	>4	4	20
P12L	ETA	>16	>16	>64	>64	N/T	>64	>64	>4	N/T	17

Table 2. CLSI breakpoints, and minimum inhibitory concentrations (MICs) for antibiotics used in this study and sample type information of 35 CRPA isolates.

P13L	ETA	>16	>16	>64	>64	N/T	>128	>64	>4	2	20
P14L	ETA	>16	>16	>64	>64	N/T	>128	>64	>4	2	N/T
P15L	Ascitic fluid	>16	>16	>64	>64	N/T	>64	>64	>4	2	22
P16L	ETA	>16	>16	>64	>64	N/T	>128	>64	>4	2	N/T
P01C	Sputum	>16	>16	4	8	4	8	<8	>2	<1	N/T
P02C	Sputum	>16	>16	>16	>16	>8*	>64	<8	>2	<1	N/T
P03C	Sputum	>16	>16	>16	16	2	>64	<8	<0.125	<1	N/T
P05C	ETA	>16	>16	4	32	>8*	16	8	>4	4	15
P06C	ETA	>16	>16	>64	>64	>8*	32	<2	>4	4	N/T
P07C	Sputum	>16	>16	>16	>16	>8*	>64	<8	>2	<1	22
P08C	Sputum	>16	>16	16	16	4	16	32	>2	<1	N/T
P09C	Gastric Aspirate	>16	>16	>16	>16	>8*	>64	<8	>2	<1	N/T
P10C	Sputum	>16	16	>16	>16	>8*	>64	16	>2	<1	N/T
P11C	Sputum	>16	>16	>16	>16	4	>64	32	>2	<1	N/T
P12C	Sputum	>16	>16	>16	>16	>8*	>64	16	>2	<1	N/T

MIC, minimum inhibitory concentration; IPM, imipenem; MEM, meropenem; CAZ, ceftazidime; FEP, cefepime; CZA; ceftazidime-avibactam; TZP, piperacillintazobactam; AMK, amikacin; CIP, ciprofloxacin; COL, colistin; TOB, tobramycin; ATM, aztreonam; OprD, outer membrANe porin D; AMR, ANtimicrobial resistance; BAL, bronchoalveolar lavage; BA, bone marrow aspirate; ETA, endotracheal aspirate; And CRPA, carbapenem-resistant *P. aeruginosa*.

*, with >8 mg/L MIC reported as R - -resistant and an "Intermediate category" is not provided by the CLSI 2022 guidelines. N/T, Not Tested -CLSI guidelines recommend the Antibiotics may warrant primary testing, but their reporting may be selective, such as when the organism is resistant to agents of the same antimicrobial class or for infection control purposes

^a MIC detected using Vitek[®]2 system (bioMérieux); ^b MIC detected using Thermo Scientific[™] Sensititre[™]; ^c MIC detected using Kirby Bauer technique MIC breakpoints were based on CLSI 2022

154

A large proportion of CRPA isolates obtained from Hospital B and C showed resistance against CAZ and FEP (62.5% and 72.7%), in contrast to the incidence of CAZ and FEP resistance in Hospital A, (37.5% And 25.0%) (FIG 1A). The same observation could be made for CIP resistance. MICs revealed moderate-level CAZ and FEP resistance (MICs >64 mg/L) against isolates obtained from Hospital A and B in contrast to Hospital C (FIG 1A).





161

FIG 1A. Percentage of resistant isolates in the three sampling sites. IPM, imipenem; MEM, meropenem; CAZ, ceftazidime; FEP, cefepime; CZA; ceftazidime-avibactam; TZP, piperacillintazobactam; AMK, amikacin; CIP, ciprofloxacin; COL, colistin; TOB, tobramycin; and ATM, aztreonam.



FIG 1B. Prevalence of CRPA isolates (n = 35) per facility and the number of antibiotics (n = 8) each
isolate was resistant against. The CRPA isolates from Hospitals B and C showed resistance against
a greater number of different antibiotics.

The MIC values of CRPA isolates showed resistance to multiple classes of antibiotics. All 177 isolates assessed in this study were resistant to at least one antibiotic (FIG 1B). The MDR 178 phenotype was observed in CRPA isolates obtained from Hospital C, 100.0% (n = 11/11), Hospital 179 180 B, 75.0% (n = 12/16) and Hospital A, 87.5% (n = 7/8) and showed resistance to at least one antibiotics in three or more antimicrobial class-tested (FIG 1B, 1C, and Supplemental File 2). Out 181 of the 16 CRPA isolates investigated from Hospital B, 75.0% (n = 12/16) are multidrug-resistant 182 (MDR). Of these, 68.75% (n = 11/16) expressed resistance against three or more groups of 183 antibiotics, while 18.2% (n = 2/11) expressed resistance to eight antibiotics tested (FIG 1B and 184 185 1C).



FIG 1C. Number of MDR and non-MDR CRPA isolates per isolation site. Hospital A, 87.5% (n = 7/8);
Hospital B, 75.0% (n = 12/16); and Hospital C, 100.0% (n = 11/11).

Genotyping using MLST analysis for 35 CRPA isolates Of the 36 CRPA isolates subjected
to whole genome sequencing, 35 CRPA isolates, eight (22.9%) from Hospital A, 16 (45.7%) from
Hospital B and 11 (31.4%) from Hospital C, met the quality control (QC) standards.

The genome validation process. (1) Sequence Read Quality: The raw sequences underwent 199 200 read trimming and quality assessment using Fastp (Chen, et al., 2018), ensuring a high Phred score 201 of 30 (Q30) for the sequence reads. (2) Genus-Level Taxonomic Classification: Using the Kraken2 Minikraken database (Wood et al., 2019; Wood & Salzberg, 2014), at least 80% of the reads that 202 passed the filter belonged to the Pseudomonas genus (Vivo et al., 2022). This high percentage of 203 204 genus-specific reads confirms the predominance of the target organisms in the sequenced 205 samples, minimizing the presence of contaminating sequences from other genera. (3) Genome Coverage: The number of reads provided at least 30x read coverage for *P. aeruginosa* genome. 206 The read coverage of 30x is generally considered sufficient for accurate genome assembly and 207

variant calling (Liu et al., 2022; Seah et al., 2023). The genome assembly and variant calling were 208 209 performed in the main workflow of the EpiTomas bioinformatics pipeline. The high coverage ensures a comprehensive representation of the genomes, allowing for reliable downstream 210 211 analyses such as resistance gene identification and strain typing. (4) Sequencing Depth: The total 212 number of reads analyzed for each P. aeruginosa genome exceeded two million. The high sequencing depth ensures that the genomes are well-represented and that the data is suitable 213 for downstream analyses, such as comparative genomics and identifying genetic determinants 214 215 associated with antimicrobial resistance. Additionally, the GC content was also checked. The 216 included P. aeruginosa genomes have a GC content ranging from 64.9 to 67.2%. These GC content ranges are consistent with the expected values for these species, further confirming the accurate 217 218 identification of the target organisms.

219 Sequence alignment against the RefGenome PA01 After pre-processing, sequence reads 220 underwent alignment against PA01 NC 002516.2 as the reference genome for *P. aeruginosa* using 221 snippy and subsequently determined the alignment coverage using mosdepth (Pedersen & Quinlan, 2018), followed by variant calling. Additionally, the predicted effect and annotation of 222 223 the called variants were performed using SnpEff (Cingolani et al., 2012). The PA01, as the chosen reference genome for *P. aeruginosa*, with RefSeq accession NC 002516.2; the genome size is 6.2 224 225 Mbp, total genes of 5,697, protein-coding genes of 5,572 and with GC content of 66.5%, and 226 available at https://www.ncbi.nlm.nih.gov/datasets/ genome/GCF 000006765.1/.

227 By meeting these quality control standards, the included samples are suitable for 228 downstream analyses, such as MGEs and resistance gene identification, strain typing, and mutation identification, which will provide valuable insights into the epidemiology and resistance
 mechanisms of *P. aeruginosa*.

Traditional MLST and cgMLST were used here to investigate the high-risk clones and genomic epidemiology using the consensus sequence of the 35 CRPA isolates investigated in this study.

A. Traditional MLST analysis The traditional MLST analysis using Pasteur nomenclature in 234 the PubMLST database (Jolley et al., 2018) revealed the highest number of unknown STS (27 235 236 singletons) and six different known STs among the 35 sequenced CRPA isolates (FIG 2A). The international high-risk clone ST111 was represented by one isolate, 6.25% (n = 1/16) obtained 237 from Hospital B. Hospital B was also represented by ST1822 (n = 1/16, 6.25%), ST357 (n = 1/16, 238 239 6.25%), ST389 (n = 1/16, 6.25%), and unknown STs represented the largest ST (n = 12/16, 75%) of the CRPA isolates obtained from this isolation site. Moreover, another global high-risk clone, 240 241 ST175, was represented by the two isolates, 18.18% (n = 2/11) obtained from Hospital C, and 242 unknown STs represented the largest ST (n = 9/11, 81.82%) of the CRPA isolates obtained from this isolation site. Hospital A was represented by ST3753, 25.0% (n = 2/8), and predominantly 243 unknown STs, 75.0% (n = 6/8) (FIG 2A). 244



253

FIG 2A. Distribution and proportion of STs of CRPA isolates per hospital using the Pasteur nomenclature in the PubMLST database (Jolley et al., 2018). The number inside the graph denotes the percentage of ST identified. The high percentage of unknown ST was identified and represented by the CRPA obtained from the three isolation sites. The right side denotes the different STs identified.

259 However, the traditional MLST analysis using Pasteur nomenclature in the Pathogenwatch 260 database (https://cgps.gitbook.io/pathogenwatch/technical-descriptions/typing-methods/mlst) 261 revealed that 77.1% (n = 27/35) of CRPA isolates, represented by singleton unknown STs 262 possessing novel allele/s represented by CRPA isolate ST with an asterisk * (FIG 2B And Supplemental File 3). An asterisk *represents novel ST with a specific allele that is unavailable or 263 unknown, and ~, an almost similar allele https://cgps.gitbook.io/pathogenwatch/technical-264 descriptions/typing-methods/mlst (Fig 2B). Hospitals A, B And C were represented by the 265 266 following proportion of unknown/novel STs: 75.0% (n = 6/8), 75.0% (n = 12/16), and 81.82% (n = 12/16), and 81.82\%

9/11), respectively (FIG 2A). In summary, 55.6% (n = 15/27) of singleton new STs possessed new
alleles, while 25.9% (n = 7/27) possessed multi-allelic (7,321) at *trpE* locus. The multi-allelic CRPA
isolates were represented by P08L, P11L, P12L, P15L, and P16L CRPA isolates, obtained from
Hospital B, and P10C and P12C CRPA isolates obtained from Hospital C (Supplemental File 3).



FIG 2B. Distribution and proportion of sequence type (ST) CRPA isolate per hospital using Pasteur
nomenclature in the Pathogenwatch database (<u>https://cgps.gitbook.io/pathogenwatch/</u>
<u>technicaldescriptions/typing-methods/mlst</u>). The right side denotes the different STs identified.
Asterisk *represents novel ST with a specific allele that is unavailable or unknown. The number
inside the graph denotes the percentage of ST identified. Unique or singleton novel ST were
identified and represented by the CRPA isolates obtained from the three isolation sites.

Based on the traditional MLST analysis, the minimum spanning was constructed. The following CRPA isolates represented the index case of each isolation site: Hospital A, P01T, Hospital B, P01L, and Hospital C, P01C. In this manuscript, the term index case refers to the first

286 CRPA isolates in August 2022, which marked the beginning of the isolate collection from the three

isolation sites. Clustering from the index cases of CRPA infections from each isolation site was not

observed (FIG 3A). The index cases from each isolation site are the following: P01T, P01L and P01C.



289

FIG 3A. Genotyping of 35 CRPA isolates based on traditional MLST scheme utilizing Pasteur nomenclature in the Pathogenwatch and the PubMLST database (Jolley et al., 2018). The circles are named according to the isolates and colored according to the isolation sites. Each circle includes the ST. The inner black circles represent the index case. In this manuscript, the index case is the first case of CRPA infections in August 2022, which marked the beginning of the isolate collection from the three isolation sites. The circles labeled with more than one sample represent

that these samples exhibited identical ST. The major cluster involving the P16L is indicated in acircle shown in FIG 3A.

298 The traditional MLST used the schema of seven housekeeping genes (acsA, aroE, auaA, 299 mutL, nuoD, ppsA, and trpE), which led to the typing and identification of two global high-risk 300 clones: ST111 represented by P07L CRPA isolate obtained from Hospital B, and ST175 represented 301 by P01C and P05C CRPA isolates obtained from Hospital C. However, one major cluster was observed involving P16L CRPA isolate represented by ST*651b, which was a sample obtained from 302 303 Hospital B and was linked to 13 isolates obtained from three different hospitals represented by 304 new STs and one isolate obtained from Hospital B represented by ST389. These CRPA isolates clustered to P16L, which was an isolate obtained from Hospital B, were observed to have shared 305 306 similar alleles in two or more loci. However, the allele profiling is based or limited only to seven loci or seven P. aeruginosa housekeeping genes. Furthermore, the PO5C and PO1C isolates 307 obtained from Hospital C were both represented as ST175, having allele differences at locus trpE 308 309 (19 and 134) when compared to P09C isolate, and allele differences at loci acsA (28, 17), nuoD (3, 310 1) and trpE (19, 3) when compared to P05L isolate that was obtained from Hospital B. Additionally, 311 The PO1L CRPA isolate, which was the index case of Hospital B, is the single ST1822 identified. Finally, two CRPA isolates, namely P05T and P01T, which were obtained from Hospital A, were 312 313 both represented as ST3753. The genotyping of the 35 CRPA isolates using traditional MLST unveiled the ubiquity of *P. aeruginosa* and required the application of cgMLST to delineate the 314 315 sporadic cases and provide high-resolution genetic distinction among 35 CRPA isolates obtained from the three isolation sites. The details of the allelic profile between 35 CRPA isolate and the 316 wild-type PA01 are shown in Supplemental File 3. 317

B. cgMLST Analysis We reanalyzed the consensus sequence of 35 CRPA isolates employing the high-resolution cgMLST schema (Tönnies et al., 2021). The cgMLST analysis for *P. aeruginosa* is not yet hosted by the Pathogenwatch database (<u>https://Pathogenwatch/</u>). Hence, the cgMLST.org database (de Sales et al., 2020) was used together with the pyMLST tool, which uses the wild-type PA01 as the seed genome (Biguenet et al., 2023). This was done due to the highly ubiquitous characteristics of the 35 CRPA isolates and the involvement of multiple sequence types, both known and new STs identified by the traditional MLST analysis.

Supplemental File four depicts the allelic profile of 35 CRPA isolates based on the cgMLST 325 schema, which analyses up to 3,867 target genes and up to 1,265,835 alleles to increase the 326 327 resolution in gene characterization. The header corresponds to the loci name established by the 328 cgMLST schema of Tonnies et al., 2021. Each number below each locus corresponds to the allele profile of each CRPA genome (e.g. WTPA01 has allele 1 at locus PA3729 while P01C has allele 3,868 329 330 at the same locus). Whereas, Supplemental File five depicts the number of allele differences or gene distinctions of each CRPA isolate based on 3,867 target genes, far from seven target genes 331 utilized in the traditional MLST analysis (e.g. Out of 3,867 target genes used by the cgMLST 332 333 schema, WTPA01 is distinct from P01C for up to 2,828 target genes, whereas, P01L is distinct from 334 P01C for up to 3,631 target genes).

A minimum spanning tree was constructed based on the cgMLST schema. Clustering was not observed from the index cases of CRPA infections, namely P01T, P01L, and P01C isolates, in three isolation sites, namely Hospital A, B, and C, based on the number of allelic differences utilizing up to 3,867 target genes and 1,265,835 alleles (FIG 3B). However, a major cluster

involving the PO6L is indicated in a circle shown in FIG 3B. PO6L CRPA isoate was obtained from 339 340 Hospital B and linked to 17 CRPA isolates obtained from three isolation sites having the allelic distinction of 1,664 to 3,551 alleles (FIG 3B). PO5L CRPA isolate obtained from the same hospital 341 (Hospital B) had the nearest genetic distinction when compared with PO6L isolate, having 1,664 342 allele differences, while PO3T isolate obtained from Hospital A has the farthest or highest genetic 343 distinction corresponding to 3,551 allelic differences from PO6L isolate (Supplemental File 5 and 344 FIG 3B). These findings showed that the sequence diversity of *P. aeruginosa* was high among the 345 346 35 isolates investigated.



347

FIG 3B. Genotyping of 35 CRPA isolates based on cgMLST schema (Tönnies et al., 2021)utilizing
 pyMLST (Biguenet et al., 2023) and cgmlst.org database (de Sales et al., 2020). The circles are
 named according to the isolates and colored according to the isolation sites. The inner black

351	circles represent the index case. The numbers on connecting lines displayed the number of allele
352	differences between each CRPA isolates investigated. The current cgMLST scheme has no
353	standardized typing of <i>P. aeruginosa</i> (Biguenet et al., 2023). The major cluster involving the PO6L
354	is indicated in a circle shown in FIG 3B.
355	Presence of metallo-beta-lactamases (MBLs) and extended spectrum beta-lactamase
356	(ESBLs)
357	The 35 CPRA isolates obtained from three tertiary hospitals in Metro Manila from August
358	2022 to January 2023 revealed high genetic diversity and exhibited a non-clonal epidemic
359	structure composed of a huge proportion of rare strains or novel STs (FIG 4). The three different
360	isolation sites, namely Hospital A, has an 815-bed capacity, Hospital B has a 650-bed capacity, and

						Ph	enoty	pic A	MR									Geno	otypic	AMR							
																	E	Beta-l	actai	nase	s					Plas	mid
Isola	_	Specim					Antib	iotics	6				I	ESBL	6	ME	BLs				0	XA				n	s
te	Room	en Type	MdI	MEM	CAZ	FEP	CZA	ЧZТ	AMK	CIP	COL	ATM	CTX-M-15	TEM-1	KPC-2	VIM-2	NDM-7	OXA-1	OXA-10	OXA-395	OXA-486	OXA-50	OXA-74	OXA-846	OXA-903	IncX3	IncP-6
P01T	Medicin	BAL	R	R	I	I	NT	I	S	I	R	R	А	А	А	А	А	А	А	А	А	А	А	А	А	А	A
P02T	Medicin e	Blood	R	R	S	S	NT	S	S	R	NT	NT	А	А	А	А	А	А	А	А	А	А	А	А	А	А	А
P03T	CCU	ETA	R	Ι	R	S	NT	Ι	S	S	NT	Т	А	А	А	А	А	А	А	А	А	А	А	А	А	А	А
P04T	Medicin e	Blood	R	R	S	S	NT	S	S	R	NT	Ι	A	A	A	А	А	А	А	A	A	А	A	А	А	А	A
P05T	Medicin e	BAL	R	R	Ι	Ι	NT	I	S	Ι	NT	R	А	A	А	А	A	A	A	Р	А	А	А	A	А	А	А
P06T	Surgery	BA	R	R	R	R	NT	R	S	S	NT	R	А	А	А	А	А	А	А	А	А	А	А	А	А	А	А
P07T	(Pediatr ic) Medicin e	Sputum	R	R	R	R	NT	R	S	S	NT	R	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A
P08T	Medicin e	ETA	R	R	S	S	NT	I	S	S	NT	R	А	А	А	А	А	А	А	А	А	А	А	А	А	А	А
P01L	Medicin e	ETA	R	R	S	S	NT	I	S	S	NT	Ι	А	А	А	А	А	А	А	А	А	А	А	Ρ		А	А
P02L	Medicin e	Blood	R	Ι	S	S	NT	S	S	S	NT	S	A	A	A	A	A	A	А	A	A	А	A	A	Ρ	А	A
P03L	ICU5	Blood	R	R	R	R	NT	Т	Ι	R	NT	S	А	А	А	А	А	А	А	А	А	А	А	А	А	А	А
P04L	Medicin e	Sputum	R	R	R	R	NT	R	S	S	NT	S	A	А	А	А	А	А	А	А	А	А	А	Ρ	А	А	А
P05L	ICU3	ETA	R	R	R	R	NT	R	R	R	NT	R	А	А	Р	Р	А	А	А	А	А	А	Р	А	А	А	Р

Table 3: The phenotypic and the genotypic antimicrobial resistance profile of 35 CRPA isolates obtained from three hospitals.

P06L	ICU3	Wound Tissue	R	R	R	R	NT	Ι	S	R	R	NT	А	А	Ρ	Ρ	А	А	А	А	А	А	Ρ	А	A	А	Ρ
P07L	CCU	ETA	R	I	S	S	NT	S	S	R	NT	R	А	А	А	А	А	А	А	Ρ	А	А	А	А	А	А	А
P08L	ICU6	Catheter Drain	R	I	S	S	NT	S	S	S	NT	S	А	А	А	А	А	А	А	А	А	А	А	А	А	А	A
P09L	Medicin e	Gastric Aspirate	R	S	S	S	NT	S	S	S	Ι	S	A	A	А	A	Α	Α	A	А	Ρ	А	A	A	A	A	A
P10L	ICU6	Gastric Aspirate	R	I	S	S	NT	Ι	S	S	Ι	NT	A	A	А	A	Α	Α	A	А	A	А	A	A	A	A	A
P11L	ICU6	ETA	R	R	R	R	NT	R	R	R	R	Ι	А	А	А	А	А	А	А	А	А	А	А	А	А	А	А
P12L	ICU5	ETA	R	R	R	R	NT	R	R	R	NT	Ι	А	А	А	А	А	А	А	А	А	А	А	А	А	А	А
P13L	ICU6	ETA	R	R	R	R	NT	R	R	R	Ι	Ι	А	А	А	А	А	А	А	А	А	А	А	А	А	А	А
P14L	ICU5	ETA	R	R	R	R	NT	R	R	R	Ι	NT	А	А	Ρ	Ρ	А	А	А	А	А	А	Ρ	А	А	А	Ρ
P15L	ICU5	Ascitic fluid	R	R	R	R	NT	R	R	R	I	S	А	А	Ρ	Ρ	А	А	А	A	А	A	Ρ	А	A	A	Ρ
P16L	ICU5	ETA	R	R	R	R	NT	R	R	R	Ι	NT	А	А	А	А	А	А	А	А	А	А	А	А	А	А	А
P01C	Medicin e	Sputum	R	R	S	S	S	S	S	R	Ι	NT	A	А	А	A	А	А	A	А	А	Ρ	A	А	A	A	A
P02C	OB-Gyn	Sputum	R	R	R	R	R	R	S	R	Ι	NT	Ρ	Ρ	А	А	А	Ρ	Ρ	А	А	А	А	А	А	А	А
P03C	Medicin e	Sputum	R	R	R	Ι	S	R	S	S	Ι	NT	А	А	А	А	А	А	А	А	А	А	А	Α	A	А	А
P05C	Medicin e	ETA	R	R	S	R	R	S	S	R	R	R	А	А	А	А	А	А	А	А	А	А	А	А	А	А	А
P06C	OB-Gyn	ETA	R	R	R	R	R	Т	S	R	R	NT	А	А	А	А	А	А	А	А	А	А	А	А	А	А	А
P07C	Medicin e	Sputum	R	R	R	R	R	R	S	R	I	S	Ρ	Ρ	А	Ρ	А	Ρ	Ρ	А	А	А	А	А	А	А	А
P08C	ICU	Sputum	R	R	Ι	I	S	S	Ι	R	Ι	NT	А	А	А	А	А	А	А	А	А	А	А	А	А	А	А
P09C	ICU	Gastric Aspirate	R	R	R	R	R	R	S	R	I	NT	A	А	А	A	А	А	A	A	A	А	A	A	A	A	A
P10C	OB-Gyn	Sputum	R	R	R	R	R	R	S	R	Ι	NT	А	А	А	А	А	А	А	А	А	А	А	А	А	А	А
P11C	ICU	Sputum	R	R	R	R	S	R	I	R	I	NT	Ρ	Ρ	А	А	Ρ	А	А	Ρ	А	А	А	А	А	Ρ	А

CRPA, carbapenem-resistant *P. aeruginosa*; ST, sequence type; ICU, intensive care unit; CCU, critical care unit; OB-Gyn, obstetrics and gynecology; BAL, bronchoalveolar lavage; BA, bone aspirate; ETA, endotracheal aspirate; ESBLs, extended-spectrum beta-lactamases; MBLs, metallo-beta-lactamases; OXA, oxacillinase; PMQR, plasmid-mediated quinolone resistance; MIC, minimum inhibitory concentration; IPM, imipenem; MEM, meropenem; CAZ, ceftazidime; FEP, cefepime; CZA, ceftazidime-avibactam; TZP, piperacillintazobactam; AMK, amikacin; CIP, ciprofloxacin; COL, colistin; ATM, aztreonam; and AMR, antimicrobial resistance.

P, present; A, absent; R, resistant; S, susceptible; I, intermediate; NT, not tested; *Represent novel ST with a specific allele that is unavailable or unknown



362

FIG 4. Phylogenetic SNP analysis of 35 CRPA obtained from three hospitals (Hospitals A, B And C) in Metro Manila, Philippines, from August 2022 to January 2023, the corresponding resistance profile, presence of AMR determinants, and specimen type. SNP analysis was performed using the wild-type (WT) PA01 (accession number: NC_002516.2) as the reference genome. The scale bar

366	shows the genetic distinction between each CRPA isolates. Vertical columns demonstrate (1) isolation site, (2) patient's room, (3)
367	specimen type, (4) sequence type, (5) resistance phenotype: resistant (red filled circle), intermediate resistant (pink filled circle),
368	susceptible (blue filled circle), Not Tested (empty circle), (6) resistance genotype including beta-lactamase genes: present (orange filled
369	squares) and absent (empty squares), (7) aminoglycoside conferring resistant genes: present (green filled squares) and absent empty
370	squares), (8) plasmid-mediated quinolone resistance (PMQR): presence (purple filled square) and absent (empty square) of acquired
371	resistance genes, (9) predominant plasmid replicon types: presence (black filled circle) and absent (empty circle). IPM, imipenem;
372	MEM, meropenem; CAZ, ceftazidime; FEP, cefepime; CZA, ceftazidime-avibactam; TZP, piperacillin-tazobactam; AMK, amikacin; CIP,
373	ciprofloxacin; COL, colistin; ICU, intensive care unit; CCU, critical care unit; OB-Gyn, obstetrics and gynecology; BAL, bronchoalveolar
374	lavage; BA, bone aspirate; ETA, endotracheal aspirate; and PMQR, plasmid-mediated quinolone resistance. Detailed results are in
375	Supplemental File 7.



FIG 5. Distribution of plasmid-encoded AMR genes in 35 CRPA isolated from three tertiary hospitals in Metro Manila, Philippines, from August 2022 to January 2023. Red and white represent the presence and absence of AMR genes in the test strains. The left side denotes the category of AMR genes. Strain names are depicted at the bottom of the chart.

The analysis revealed that VIM-2 co-produced with KPC-2 and OXA-74 were identified in P05L, P06L, P14L, and P15L isolates obtained from patients admitted to ICU of Hospital B. In all four CRPA isolates, the KPC-2 gene was flanked by ISKpn6 And ISPay42, while the VIM-2 gene in the same isolates was flanked by Tn*As3*. P05L CRPA isolate was obtained from ETA of 73/M; P06L CRPA isolate from wound tissue of 70/M, P14L CRPA isolate was recovered from ETA of 80/F; and

P15L CRPA isolates from ascitic fluid of 66/M patient (Table 3, FIG 4, 5, and 6). The investigations 385 386 also revealed MBL VIM-2 co-produced with ESBLs TEM-1 and CTX-M-15, in PO7C CRPA isolate obtained from the sputum of 70/F patient admitted to the medicine unit of Hospital C and was 387 diagnosed as having community-acquired pneumonia. The 70/F patient was given IPM and TZP 388 389 as part of her medication. The phenotypic AMR revealed resistance against IPM, MEM, CAZ, FEP, CZA, TZP, CIP and intermediate against COL. Interestingly, the IncX3 plasmid replicon type was 390 identified from the P11C CRPA isolate that co-produced MBL NDM-7 and ESBLs TEM-1 and CTX-391 392 M-15. In addition, P11C CRPA isolate was obtained from the sputum of 25/M with meningitis 393 admitted in the ICU of Hospital C. The 25/M patient was given the following medications: TZP, CRO, and FEP. The phenotypic AMR showed resistance against IPM, MEM, CAZ, FEP, TZP, CIP and 394 395 intermediate against COL (Table 3, FIG 4, and 5).

Carbapenemases, and ESBL genes are known to be distributed by plasmids and other MGEs such as insertion sequence and transposonand speed up the spread and acquisition of ARGs (Manohar et al., 2021; Ramirez et al., 2014; Reul and et al., 2015).

399 Presence of Insertion Sequence (IS) and Transposon Small mobile genetic elements called IS and composite transposons are essential for the transfer of antibiotic resistance genes 400 401 (ARGs) among bacterial populations (Rice, 2008). Transposition mechanisms allow IS to migrate within a single cell along with resistance genes associated with them (Llaca-Díaz et al., 2013). 402 403 Composite transposons, defined as areas enclosed by two identical or similar IS copies, have the 404 ability to transport resistance genes and facilitate their transfer between distinct DNA molecules (Siguier et al., 2015). The presence of drug resistance against multiple antibiotics, the potential 405 high-risk clones identified and the presence of ARGs, specifically carbapenemases and 406

407 cephalosporinases that are flanked by MGEs pose a potential threat in healthcare settings
408 (Partridge et al., 2018). The spread of genes that confer antibiotic resistance in bacteria is
409 facilitated by these MGEs (Yoon & Jeong, 2021). A schematic diagram of representative ARGs and
410 MGEs is shown in Figure 6.



411 **FIG 6.** Schematic diagram of representative ARGs flanked by the MGEs in seven CRPA isolates.

The KPC-2 gene, in P05L, P06L, P14L, and P15L CRPA isolates are flanked by ISK*pn6*, ISP*ay42*, and ISB*ma3*, while VIM-2 and OXA-74 genes in the same isolates are flanked by Tn*As3*. The NDM-7 gene in CRPA isolate P11C is flanked by IS5D, ISA*ba125*, and ISM*po4*, whereas TEM-1 gene in CRPA isolates P02C, P07C, and P11C is flanked by ISE*c63*, Tn2, Tn*5393*, and IS15DIV, and CTX-M-15 in the same CRPA isolates is flanked by ISE*cp1*, and Tn2. The OXA-10 in P02C and P07C isolates are flanked by TnAs3 and ISAba43 (FIG 6).

Presence of IncX3 and IncP-6 Plasmid Replicon Types Plasmids have the ability to transfer 418 419 AMR genes to other bacteria, which can speed up the spread and evolution of bacterial pathogens (Teixeira et al., 2023). Antimicrobial resistance genes in P. aeruginosa and other Gram-420 negative bacteria are largely transferred by the IncP-6 and IncX3 plasmids. While the IncX3 421 422 plasmids have a narrow host range but are highly stable and have great conjugation ability, making them important targets for research and surveillance in the fight against antimicrobial 423 424 resistance (Guo et al., 2022), the IncP-6 plasmids have a broad host range and can transfer and 425 replicate in most Gram-negative bacteria (Dai et al., 2016). Plasmids within the 35 sequenced CRPA isolates were differentiated based on plasmid replicon types. The IncX3 (2.9%, n = 1/35) 426 and IncP-6 (11.4%, n = 4/35) accounted for the prevalent plasmid replicon types detected in the 427 428 CRPA isolates. P11C CRPA isolate obtained from Hospital C was positive for IncX3, whereas P05L, 429 P06L, P14L, and P15L CRPA isolates obtained exclusively from Hospital B were positive for IncP-6 430 (Table 3 and FIG 4). The IncX3 plasmid replicon is the most common subgroup found to harbor NDM and KPC (Guo et al., 2022; Liakopoulos et al., 2018), contrary to the single isolate found 431 positive for IncX3 plasmid replicon in our study. 432

Presence of plasmid-mediated quinolone resistance (PMQR) genes Due to their ability 433 434 to transmit horizontally and decreased susceptibility to fluoroquinolones, PMQR genes are important in conferring *P. aeruginosa* with resistance to these antibiotics. The fluoroquinolones 435 ciprofloxacin and norfloxacin are less effective when modified by aac(6')-Ib-cr, whereas the Qnr 436 437 genes encode proteins that protect DNA gyrase and topoisomerase (Venkataramana et al., 2022). In this study, the PMQR genes were identified in 14.3% (n = 5/35) of the CRPA isolates 438 investigated. The QnrS1 (2.9%, n = 1/35) was identified from P11C CRPA isolate obtained from 439 440 Hospital C, while the QnrVC1 was identified from (5.7%, n = 2/35) P06L CRPA isolate obtained from Hospital B and P12C isolate obtained from Hospital C. Moreover, the ciprofloxacin and 441 aminoglycoside modifying enzyme (aac-(6')-lb-cr) were identified from P02C and P07C isolates 442 443 obtained from Hospital C, accounting to 2.9%, (n = 1/35). Of the 62.9% (n = 22/35) CRPA isolates shown to be phenotypically CIP resistant, only 22.7% (n = 5/22) harbored the PMQR genes (Table 444 445 3 and FIG 4 and 5). Additionally, this study looked at mutations in gyrA and parE that could also 446 contribute to the CIP resistance (Supplemental File 6B).

The presence of mutation in the Quinolone Resistance-Determining regions (QRDR) -447 gyrA and parE genes Resistant to CIP in P. aeruginosa has been associated with mutations in the 448 449 QRDR of the gyrA and parE genes. It has been demonstrated that high-level resistance to CIP in P. aeruginosa isolates is encoded by mutations in both the gyrA and parE genes. Furthermore, 450 451 mutations in the parE gene, specifically when they coexist with mutations in qyrA or parC, are a 452 contributing factor to high-level CIP resistance (Arabameri et al., 2021). The combination of these mutations results in structural changes to DNA gyrase, which lowers the enzyme's susceptibility 453 to antibiotics and promotes drug resistance (Arabameri et al., 2021). 454

SNPs T831 was identified in the gyrA gene A473V was identified in the parE gene in 31.4% 455 456 (n = 11/35) and 5.7% (n = 2/35) CRPA isolates investigated. T83I and A473V mutations have been known to cause resistance to fluoroquinolones. The CRPA isolates that harbored *avrA* mutations 457 (T83I) are isolates: P02T, P04T, P05L, P06L, P14L, P15L, P01C, P02C, P05C, P07C and P11C, while 458 459 PO2T and PO4T isolates obtained from Hospital A harbored parE mutations (A473V). All CRPA isolates that exhibited both or either of the parE and GyrA mutations and at least one of the 460 PMQR genes demonstrated resistance against CIP. However, 45.4% (n = 10/22) of CRPA isolates 461 462 that displayed phenotypic resistance against CIP did not possess gyrA and parE mutations, 463 including PMQR gene expression (Supplemental File 6B and 7). Presence of aminoglycoside conferring resistance genes Genes mediating 464 aminoglycoside resistance were also identified from 20.0% (n = 7/35) of CRPA isolates 465 investigated exclusively recovered from Hospital B and C. ANT-(3")-IIa has the highest proportion 466 467 among the identified aminoglycoside conferring resistance genes, 17.1% (n = 6/35). ANT(2")-Ia, 468 APH(6)-Id, APH(3'')-Ib, APH(3')-IIc, AAC(3)-IIe, AAC(6')-Ib10, And AAC(6')-Ib3, were also detected from both Hospital B and C isolates and each gene accounting to 5.7% (n = 2/35). Also 469 present are APH(3")-Ib, APH(3')-IIc, APH(9)-Ic, and aadA2 each gene accounting to 2.9% (n = 470 1/35). Of these, 43.0% (n = 3/7) were phenotypically expressed. Moreover, the resistance 471 472 determinants for the observed AMK resistance were not detected in 57.1% (n = 4/7) of the CRPA 473 isolates investigated (FIG 4 and 5 and Supplemental File 7).

Incidence of OprD mutations Resistance in CRPA isolates that do not produce carbapenemases could be mediated by a loss of porin D (OprD) and/or overexpression of efflux pumps (such as MexAB-OprM) (Amsalu et al., 2020; Arzanlou et al., 2017; Gashaw et al., 2024;

Nieto-Saucedo et al., 2023). OprD is an outer membrane porin in *P. aeruginosa* that facilitates
the uptake of basic amino acids and imipenem (Alcock et al., 2023). However, mutations in the
OprD that will correlate with carbapenem resistance, such as Gln143X, were not detected in all
CRPA isolates investigated (Supplemental File 6A).

481 **DISCUSSION**

P. geruginosa that produce beta-lactamases specifically carbapenemases is a global 482 problem. The assessment was performed utilizing an in-depth analysis of the whole genome 483 484 sequence of 35 non-duplicate CRPA isolates obtained from patients admitted from three hospitals 485 collected over the period of six months. Despite measures implemented in the isolation sites to combat AMR through antimicrobial stewardship, surveillance, and understanding of AMR, the 486 487 prevalence of AMR remains a significant challenge in patient care, particularly in Hospitals B and C, with a high proportion of CRPA isolates carrying acquired AMR genes, and a moderate to high 488 489 level of resistance against the last line of antibiotics. Four of the so-called "big five carbapenemases," namely NDM, VIM, KPC, And OXA, were identified in this study. 490

This article first reported on the co-production of KPC-2, VIM-2, and OXA-74 represented by 491 potential high-risk clones P. aeruginosa ST389, ST*95c6, ST*f555, and ST*ab6a, and in the 492 Philippines. In hospital settings, epidemic outbreaks of *P. aeruginosa* MDR/XDR high-risk clones 493 494 are usually associated with ST111 And ST175 (Cabot et al., 2012; Horcajada et al., 2019; Kocsis et 495 al., 2021; Oliver et al., 2015); however, this was not the outcome in our investigation of the 35 CRPA isolates obtained from the three hospitals. Hospitals B and C displayed a high proportion of 496 CRPA isolates carrying acquired AMR genes, specifically carbapenemases such as VIM-2 and co-497 produced with KPC-2 and OXA-74, whereas Hospital C had a large proportion of CRPA isolates 498

carrying ESBLs such as CTX-M-15 and TEM-1. In contrast, in the Department of Health's (DOH) 499 500 Antimicrobial Resistance Surveillance Reference Laboratory (ARSRL) annual report, VIM, NDM, and ESBLs were not observed; instead IMP-4 was detected in one P. geruginosa isolate obtained 501 502 from an in-line catheter (Department of Health - RITM, 2022). In addition to the rapid 503 dissemination and acquisition through horizontal gene transfer, NDM, VIM, KPC, and some OXA variants are plasmid-borne carbapenemase-encoding genes that present challenges in the 504 treatment of bacterial infections. These genes have the capacity to hydrolyze nearly all beta-505 506 lactam antibiotics, including carbapenems (Leungtongkam et al., 2018; Manohar et al., 2021; 507 Murray et al., 2022; Reyes et al., 2023; US Department of Health and Human Services; CDC., 2019). 508

509 In our report, KPC-2, VIM-2, OXA-74, NDM-7 and ESBLs were flanked by MGEs that will add burden in the mitigation of spread and acquisition through horizontal gene transfer. In 510 511 addition, one of five (1/5) CRPA isolates that were identified as positive for KPC-2 and VIM-2 was 512 found resistant to CZA. Further surveillance and investigation are suggested since it was studied that when it comes to isolates that produce KPC, CZA is highly active while remaining inactive 513 against pathogens that produce MBLs (Horcajada et al., 2019). However, the same isolate was 514 also positive for MBL VIM-2 that added burden to treatment management. A study reported KPC-515 516 2 genes located between ISKpn6-like and ISKpn8-like MGEs (Hu et al., 2021). However, in our 517 study, KPC-2 is located between ISPsy42 and ISKpn6, VIM-2 is flanked by TnAs3, while NDM-7 is surrounded by IS5D and ISMpo4. These can facilitate the movement of resistance genes between 518 519 different DNA molecules (Rice, 2008).

medRxiv preprint doi: https://doi.org/10.1101/2024.06.06.24308581; this version posted June 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

A multinational study identified the differences in the prevalence and types of 520 521 carbapenemases harbored by CRPA across different regions and found that carbapenemases were rare in CRPA isolates in the U.S. but common in isolates in other regions such as South And 522 523 Central America, particularly KPC-2 and VIM-2 (Reyes et al., 2023). Another study reported that 524 CRPA ranges from 10 to 30% in countries such as Australia and North America to more than 50% in Saudi Arabia, Brazil, Iran, Poland, Peru, Greece, Russia, and Costa Rica, where resistance rates 525 are high enough to be concerning for public health (Halat & Moubareck, 2022; Hong et al., 526 527 2015b). Reports confirmed the geographic differences in carbapenemase genotypes, such as the 528 U.S. epidemic was linked to KPC (class A in the Ambler classification) (Bush & Jacoby, 2010), the European epidemic to VIM (class B) and OXA-48-like (class D), and the Asian epidemic to NDM 529 and IMP (class B) (Suzuki et al., 2019). The NDM type is epidemic in clinical settings in the 530 531 Philippines. In fact, a study on beta-lactam-resistant Gram-negative bacilli clinical isolates in a 532 Philippine tertiary care hospital co-produced NDM-1, TEM-5, CTX-M-117, IMP-4, OXA-1, and OXA-533 72 in one P. aeruginosa isolate, while another P. aeruginosa isolate co-harboring NDM-1, IMP-1, OXA-1, and OXA-72 (Abordo et al., 2023). Similarly, we also identified in our study, P11C a CRPA 534 isolate carrying NDM-7 that co-produced CTX-M-15, TEM-2, and OXA-395 and is represented by 535 novel ST*4b1c. This isolate was positive for the IncX3 type plasmid replicon and the ARGs were 536 537 surrounded and flanked by MGEs making the P11C CRPAS a potential high-risk clone. The P11C 538 CRPA isolate from Hospital C was obtained from the sputum of a 26-year-old male ICU patient who was treated with piperacillin-tazobactam, ceftriaxone, and cefepime. Furthermore, another 539 investigation underscored the global clinical implications of CRPA, noting that its genetic and 540 epidemiological attributes are poorly understood (Chen et al., 2018), and there is a need for 541

medRxiv preprint doi: https://doi.org/10.1101/2024.06.06.24308581; this version posted June 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

further research to understand their genetic and epidemiological attributes. In this article, we 542 543 elucidated the genetic and epidemiologic characteristics of the 35 CRPA strains, specifically the co-production of VIM-2 and KPC-2 in P05L, P06L, P14L, and P15L CRPA strains obtained from ICU 544 patients in Hospital B. These CRPA strains are both IPM and MEM-resistant. In other published 545 546 studies, ST175 is frequently observed to produce VIM-2, whereas ST111 can produce KPC-2 carbapenemase (Oliver et al., 2015); however, this was not the case in our investigation because 547 ST175 and ST111 did not contain any MBLs and ESBLs, instead, the novel STs were the clones 548 549 responsible for the co-production of VIM-2, KPC-2, and OXA-74. The genetic heterogeneity of 35 550 CRPA isolates investigated in this study contrasts with the clonal dominance of high-risk clones in other studies (Cabot et al., 2012; Oliver et al., 2015; Pollini et al., 2013). However, the limited 551 552 sample size and short duration of sample collection can be a factor.

The 35 CPRA isolates obtained from three tertiary hospitals in Metro Manila from August 2022 to January 2023 exhibited high phenotypic and genetic diversity (FIG 6). The presence of multiple drug resistance CRPA strains and multiple antibiotic-resistance genes that are flanked by mobile genetic elements (MGE) (FIG 6) pose a potential threat in healthcare settings. A more stringent protocol needs to be in place, particularly for the sites that showed a high proportion of AMR and a high level of resistance against the last line of treatment.

559 CONCLUSIONS

This research presented an insight into the current genetic characteristics of 35 CRPA isolates obtained from August 2022 to January 2023 from the three tertiary hospitals in Metro Manila, Philippines, highlighting the first identification of the CRPA harboring plasmid-borne VIM-2, and co-produced with KPC-2, And OXA-74 flanked by MGEs. Additionally, the persistent

identification of NDM in the Philippine's clinical setting remains a major global public health concern. Control strategies should be strongly implemented, along with discovering inhibitors targeting carbapenemase-producing *P. aeruginosa*. The genetic and epidemiologic characterization of clinical CRPA isolates, in addition to surveillance, are of the utmost importance in order to enhance the outcomes of infection control measures designed to mitigate the incidence and spread of CRPA infection by providing current information.

570

571 MATERIALS AND METHODS

Isolation and Collection of P. aeruginosa. From August 2022 to January 2023, 40 CRPA 572 isolates were obtained from the three tertiary hospitals in Metro Manila, Philippines. The 573 Vitek[®]2 system (bioMérieux) and/or BD Phoenix[™] M50 instrument was used for species 574 575 identification, and the strains that showed imipenem and/or meropenem resistance with MIC 576 breakpoints of ≥8.0 mg/L as the result of antibiotic susceptibility using the Vitek[®]2 system (bioMérieux) and /or BD Phoenix[™] M50 instrument, were collected. *P. aeruginosa* Strains that 577 demonstrated MIC breakpoints of $\geq 8.0 \text{ mg/L}$ to carbapenem (imipenem and or meropenem) 578 were designated as CRPA and were included in the study provided that the source CRPA isolates 579 are the following: lower respiratory tract, wound discharge, blood, and other sterile body fluids. 580 581 Other sources, such as stool, throat, And nasal swabs, were excluded from the collection. Out of 40 CRPA isolates, 36 were successfully sub-cultured, and pure colonies were isolated for DNA 582 extraction. Thirty-six CRPA strains were subsequently subjected to WGS, but one sample was 583 584 removed due to low-quality sequence reads, and 35 were included in downstream analysis.

Antimicrobial susceptibility test. The antibiotic susceptibility test was performed using 585 586 the GN N261 CARD of Vitek[®]2 system (bioMérieux) for the following Antibiotics: IPM, MEM, FEP, CAZ, CIP, TZP, And AMK. In addition, the MIC for COL and CZA was determined using the 587 EURGNCOL plate of the Sensititre system[™] (Thermo Fisher Scientific[™]) via the commercial broth 588 589 microdilution kit And the standard broth microdilution (BMD), performed according to the CLSI CLSI M100 ED32:2022 guideline (CLSI, 2022). Kirby Bauer technique for the determination of 590 antimicrobial resistance against ATM was used. The Antimicrobial susceptibility of the strains was 591 592 determined according to the guidelines And breakpoint of the Clinical Laboratory Standard Institute (CLSI) M100-ED32:2022, with P. aeruginosa ATCC 27853 used as the quality control 593 strains (CLSI, 2022). 594

DNA extraction DNA was extracted using DNeasy[®] UltracleAN[®] Microbial Kit (Qiagen[™], Germantown, MD, USA) from cells grown overnight at 37 °C in Tryptic Soy Broth (TSB) following the manufacturer's protocol with slight modifications in the speed and time set for centrifugation. DNA concentrations were measured on Qubit using Invitrogen Qubit[™] 4 Fluorometer. For the quality of the DNA, it was performed using FLUOstar[®] Omega.

600 Whole-genome sequencing and analysis. The DNA extracts of 36 CRPA clinical isolates 601 underwent sequencing in SA Pathology (Adelaide, Australia) using the Illumina NextSeq 550 602 platform employing 150-base pair-end reads sequencing. The Amplicon Library was prepared 603 using the Nextera XT DNA Library Preparation kit (Illumina Inc., USA) following the manufacturer's 604 protocol.

605 **Data Processing and Analytics** The raw sequence data were uploaded onto an in-house 606 bioinformatics pipeline, called EpiTomas v1.0.0 (<u>https://github.com/abulenciamiguel/EpiTomas</u>).

607 EpiTomas offers an automated workflow for quality control evaluation, reference-based 608 assembly, de novo assembly, and genome characterization (FIG 7).

Raw read quality control The raw sequences underwent read trimming and quality assessment using Fastp (Chen et al., 2018). Thirty-five (35) CRPA isolates met the quality control standards, having sequence read with a Phred score of 30 (Q30), ensuring a high level of accuracy, and 80% of the reads that passed the filter belonged to *Pseudomonas* genus using Kraken2 Minikraken (Wood et al., 2019) database, with the number of reads providing at least 30x read coverage, ensuring comprehensive coverage of the genome and the genome must have a GC content ranging from 65 to 67%.

616 Sequence alignment against PA01 RefGenome and varint calling After pre-processing, 617 reads underwent alignment against PA01 NC_002516.2 as the reference genome using snippy, 618 and subsequently determined the alignment coverage using mosdepth (Pedersen & Quinlan, 619 2018). Additionally, the predicted effect and annotation of the called variants were performed 620 using SnpEff (Cingolani et al., 2012). The PAO1, as the chosen reference genome, was completely sequenced by the year 2000, and its genome is relatively large (5.5–7 Mbp) in comparison to 621 other bacteria that have been sequenced (Stover et al., 2000). Furthermore, plasmid contigs of 622 623 the 35 CRPA strains were assembled from the trimmed fastq files using plasmidSPAdes (Antipov et al., 2016). 624

AMR genes And flanking mobile genetic elements detection The assembled genomes and the plasmid contigs undergo further analysis, such as identification and characterization of AMR genes using the Resistance Gene Identifier (RGI) with the Comprehensive Antibiotic Resistance Database (CARD) as a reference (Alcock et al., 2020). Mobile genetic elements

flanking 1,000 bp up- and downstream the selected seven AMR genes (i.e., *bla*VIM-2, *bla*KPC-2,

blaNDM-7, blaTEM-1, blaCTX-M-15, blaOXA-74, blaOXA-1, and blaOXA-10) in plasmid contigs
were identified using ISfinder webtool (Siguier et al., 2006).

Traditional MLST and cgMLST analyses. Genotyping was performed using MLST for 35 632 CRPA isolates obtained from the three tertiary hospitals in Metro Manila, Philippines. P. 633 aeruginosa MLST profiles were predicted using Pasteur nomenclature in the Pathogenwatch 634 (https://cgps.gitbook.io/pathogenwatch/technical-descriptions/typing-methods/mlst) 635 and 636 PubMLST database (Curran et al., 2004; Jolley et al., 2018; Jolley & Maiden, 2010). Pathogenwatch is a free, accessible, real-time microbial genome analysis platform that provides 637 detailed and integrated genomic and epidemiological data. PubMLST provides Pathogenwatch's 638 639 schemes, and an in-house search tool is used to ensure accurate MLST and cgMLST assignments (Sánchez-Busó et al., 2021). MLST is based on a community-agreed list of seven gene loci found 640 641 in all species strains, with a code assigned to each allele (Curran et al., 2004; Jolley et al., 2018; 642 Jolley & Maiden, 2010).

Additionally, cgMLST schema (Tönnies et al., 2021) a high-resolution typing was 643 conducted using pyMLST (Biguenet et al., 2023) and the cgMLST.org database (de Sales et al., 644 645 2020) because of the ubiquitous characteristics of the 35 CRPA isolates and the involvement of multiple sequence types both known and new STs revealed by the traditional MLST. pyMLST is a 646 647 Python tool that uses a broader selection of genes from the complete or core genome for 648 bacterial phylogeny and typing (Biguenet et al., 2023). The strain's sequence type (ST) is determined by the combination of the several alleles that each distinct sequence corresponds to 649 (Biguenet et al., 2023). pyMLST allows for the iterative expansion of strain collections for 650

comparison by storing MLST profiles and allele sequences in a local SQLite database (Biguenet et 651 652 al., 2023; Tönnies et al., 2021). Using BLAST-Like Alignment Tool (BLAT). PyMLST's method aligns the first allele of each gene in the cg/wgMLST schema to the target bacterial genome of interest 653 654 Biguenet et al., 2023). MAFFT is a tool used to align incomplete genes in the cg/wgMLST schema, 655 allowing precise data analysis and SQLite database storage (Biguenet et al., 2023). With PyMLST, users can generate schemas from their own data or download pre-existing schemas straight from 656 657 sites like https://www.cgmlst.org/ncs. In this case, the cgMLST.org database was used. The 1,316 658 whole genomes of P. aeruginosa that were obtained from the NCBI were used to create the 659 cgMLST.org database, which can anaalyze 1,265,835 alleles in the nomenclature server and 3,867 locus counts (de Sales et al., 2020; Tönnies et al., 2021). 660

661 **Phylogenetic Analysis** The minimum spanning tree was constructed using GrapeTree's 662 MSTreeV2 (72) algorithm to assess the *P. aeruginosa* clonality based on allele differences and 663 determine the epidemiological landscape. In addition, IQ-TREE2 (Minh et al., 2020) was used to 664 construct the maximum likelihood tree with 1000 bootstrap replicates to assess *P. aeruginosa* 665 genetic diversity based on single nucleotide mutation.



- 666 **FIG 7.** The in-house bioinformatics pipeline was used in the analysis. Available at
- 667 <u>https://github.com/abulenciamiguel/EpiTomas</u>
- 668 Data availability. Reads from all sequence samples (fastq files) are available under the
- 669 BioProject accession PRJNA1045071 and were made public in July 2025.
- 670 Ethics declarations: Ethical permission was approved by the Ethics Committee of the University
- of Santo Tomas Hospital on August 2022 under Protocol Reference No.: REC-2022-04-
- 672 061-IS And the Institution's approval for the two hospitals.
- 673 **Funding:** No funding sources
- 674 **Conflict of interest:** No conflict of interest.

675

676 SUPPLEMENTAL MATERIALS

- 677 Excel File for Supplemental Files 1 to 7.
- 678

679 ACKNOWLEDGMENT

Isolates were provided by the Microbiology Department of the University of Santo Tomas

Hospital, St. Luke's Medical Center, Quezon City, and Chinese General Hospital and Medical

- 682 Center, Manila. Assistance from Ms. Florelei Ordañez Alva, RMT; Mr. Miguel Alpez, RMT; Mr.
- 683 Russell Gambito Panem, RMT; and Ms. Maria Eliza G. Apo, RMT.
- 684 Assistance was provided by Ms. Therris Mae Mamerto, MSc, Mr. Rinnel Bonifacio, Mr.

685 Cleve Vergara, and Mr. Adriane Villavieja of the CMDR – UST laboratory.

- 686 Coordination from A/Prof. Matthew Sykes, Ph.D. of the University of South Australia, Prof.
- 687 Edilberto P. Manahan, Ph.D., Prof. Agnes Castillo, Ph.D., and Prof. Dean Aleth Therese Dacanay,
- 688 Ph.D. of the Faculty of Pharmacy, University of Santo Tomas.
- The authors would also like to acknowledge Aldrin V. Imbag and Francisco Gerardo M.

690 Polotan for providing the compute resources utilized in this study.

691

692 **REFERENCES**

Abordo, A. M. S., Carascal, M. B., Remenyi, R., Dalisay, D. S., & Saludes, J. P. (2023). Clinically
Isolated β-Lactam-Resistant Gram-Negative Bacilli in a Philippine Tertiary Care Hospital
Harbor Multi-Class β-Lactamase Genes. *Pathogens*, *12*(8).
https://doi.org/10.3390/pathogens12081019

697 Alcock,	B. P.,	Huynh	, W., Cha	il, R.	, Smith	, K. W.	, Raphenya	, A. R.	, Wlodarski	, M. A.	, Edalatmand
-------------	--------	-------	-----------	--------	---------	---------	------------	---------	-------------	---------	--------------

- A., Petkau, A., Syed, S. A., Tsang, K. K., Baker, S. J. C., Dave, M., Mccarthy, M. C., Mukiri, K. M.,
- 699 Nasir, J. A., Golbon, B., Imtiaz, H., Jiang, X., Kaur, K., ... Mcarthur, A. G. (2023). CARD 2023:
- 700 expanded curation, support for machine learning, and resistome prediction at the
- 701 Comprehensive Antibiotic Resistance Database. *Nucleic Acids Research*, *51*(1 D), D690–D699.
- 702 https://doi.org/10.1093/nar/gkac920
- Alcock, B. P., Raphenya, A. R., Lau, T. T. Y., Tsang, K. K., Bouchard, M., Edalatmand, A., Huynh, W.,
- 704 Nguyen, A. L. V., Cheng, A. A., Liu, S., Min, S. Y., Miroshnichenko, A., Tran, H. K., Werfalli, R.
- E., Nasir, J. A., Oloni, M., Speicher, D. J., Florescu, A., Singh, B., ... McArthur, A. G. (2020). CARD
- 2020: Antibiotic resistome surveillance with the comprehensive antibiotic resistance
- 707 database. *Nucleic Acids Research, 48*(D1), D517–D525. https://doi.org/10.1093/nar/gkz935
- Amsalu, A., Sapula, S. A., Lopes, M. D. B., Hart, B. J., Nguyen, A. H., Drigo, B., Turnidge, J., Leong,
- L. E. X., & Venter, H. (2020). Efflux pump-driven antibiotic and biocide cross-resistance in
- 710 pseudomonas Aeruginosa isolated from different ecological Niches: A case study in the
- 711 development of multidrug resistance in environmental hotspots. *Microorganisms*, 8(11), 1–
- 712 18. https://doi.org/10.3390/microorganisms8111647
- Amsalu, A., Sapula, S. A., Whittall, J. J., Hart, B. J., Bell, J. M., Turnidge, J., & Venter, H. (2021).
- 714 Worldwide distribution and environmental origin of the Adelaide imipenemase (AIM-1), a
- potent carbapenemase in Pseudomonas aeruginosa. *Microbial Genomics*, 7(12).
- 716 https://doi.org/10.1099/mgen.0.000715

- 717 Antipov, D., Hartwick, N., Shen, M., Raiko, M., Lapidus, A., & Pevzner, P. A. (2016). PlasmidSPAdes:
- Assembling plasmids from whole genome sequencing data. *Bioinformatics*, 32(22), 3380–
- 719 3387. https://doi.org/10.1093/bioinformatics/btw493
- Arabameri, N., Heshmatipour, Z., Ardebili, S. E., & Bidhendi, Z. J. (2021). The role of gene
 mutations (Gyra, parc) in resistance to ciprofloxacin in clinical isolates of pseudomonas
 aeruginosa. *Iranian Journal of Pathology*, 16(4), 426–432.
- 723 https://doi.org/10.30699/ijp.2021.520570.2542
- 724 Argimón, S., Masim, M. A. L., Gayeta, J. M., Lagrada, M. L., Macaranas, P. K. V., Cohen, V., Limas,
- 725 M. T., Espiritu, H. O., Palarca, J. C., Chilam, J., Jamoralin, M. C., Villamin, A. S., Borlasa, J. B.,
- 726 Olorosa, A. M., Hernandez, L. F. T., Boehme, K. D., Jeffrey, B., Abudahab, K., Hufano, C. M., ...
- 727 Carlos, C. C. (2020). Integrating whole-genome sequencing within the National Antimicrobial
- 728 Resistance Surveillance Program in the Philippines. *Nature Communications, 11*(1).
- 729 https://doi.org/10.1038/s41467-020-16322-5
- 730 Arowolo, M. T., Orababa, O. Q., Olaitan, M. O., Osibeluwo, B. V., Essiet, U. U., Batholomew, O. H.,
- 731 Ogunrinde, O. G., Lagoke, O. A., Soriwei, J. D., Ishola, O. D., Ezeani, O. M., Onishile, A. O., &
- 732 Olumodeji, E. (2023). Prevalence of carbapenem resistance in Acinetobacter baumannii and
- 733 Pseudomonas aeruginosa in sub-Saharan Africa: A systematic review and meta-analysis. *PLoS*
- 734 ONE, 18(11 November). https://doi.org/10.1371/journal.pone.0287762
- 735 Arzanlou, M., Chai, W. C., & Venter, H. (2017). Intrinsic, adaptive and acquired antimicrobial
- resistance in Gram-negative bacteria. *Essays in Biochemistry*, *61*(1), 49–59.
- 737 https://doi.org/10.1042/EBC20160063

- 738 Biguenet, A., Bordy, A., Atchon, A., Hocquet, D., & Valot, B. (2023). Introduction and benchmarking
- of pyMLST: open-source software for assessing bacterial clonality using core genome MLST.
- 740 *Microbial Genomics*, *9*(11). https://doi.org/10.1099/mgen.0.001126
- 741 Bogiel, T., Prażyńska, M., Kwiecińska-Piróg, J., Gospodarek-Komkowska, E., & Mikucka, A. (2021).
- 742 Carbapenem-resistant pseudomonas aeruginosa strains-distribution of the essential
- 743 enzymatic virulence factors genes. Antibiotics, 10(1), 1–10.
- 744 https://doi.org/10.3390/antibiotics10010008
- 745 Bush, K., & Jacoby, G. A. (2010). Updated functional classification of β-lactamases. In Antimicrobial
- 746 Agents and Chemotherapy. https://doi.org/10.1128/AAC.01009-09
- 747 Cabot, G., Ocampo-Sosa, A. A., Domínguez, M. A., Gago, J. F., Juan, C., Tubau, F., Rodríguez, C.,
- 748 Moyà, B., Peña, C., Martínez-Martínez, L., & Oliver, A. (2012). Genetic markers of widespread
- 749 extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrobial Agents

750 and Chemotherapy, 56(12), 6349–6357. https://doi.org/10.1128/AAC.01388-12

- 751 CDC. (2019). Antibiotic resistance threats in the United States.
 752 https://doi.org/10.15620/cdc:82532
- 753 Chen, S., Zhou, Y., & Gu, J. (2018). Fastp: An ultra-fast all-in-one FASTQ preprocessor.

Bioinformatics, *34*(17), i884–i890. https://doi.org/10.1093/bioinformatics/bty560

- Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D.
- 756 M. (2012). A program for annotating and predicting the effects of single nucleotide
- polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-
- 758 2; iso-3. Fly Landes Bioscience, 6(2), 80–92. https://doi.org/10.4161/fly.19695
- 759 CLSI. (2022). M100 Performance Standards for Antimicrobial. CLINICAL AND LABORATORY.

- Curran, B., Jonas, D., Grundmann, H., Pitt, T., & Dowson, C. G. (2004). Development of a multilocus
- sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. *Journal*
- 762 of Clinical Microbiology, 42(12), 5644–5649. https://doi.org/10.1128/JCM.42.12.5644-
- 763 5649.2004
- 764 Dai, X., Zhou, D., Xiong, W., Feng, J., Luo, W., Luo, G., Wang, H., Sun, F., & Zhou, X. (2016). The IncP-
- 765 6 plasmid p10265-KPC from Pseudomonas aeruginosa carries a novel ΔISEc33-associated
- 766 blaKPC-2 gene cluster. *Frontiers in Microbiology,* 7(MAR).
- 767 https://doi.org/10.3389/fmicb.2016.00310
- de Sales, R. O., Migliorini, L. B., Puga, R., Kocsis, B., & Severino, P. (2020). A Core Genome
- 769 Multilocus Sequence Typing Scheme for Pseudomonas aeruginosa. Frontiers in Microbiology,
- 770 *11*. https://doi.org/10.3389/fmicb.2020.01049
- 771 Department of Health RITM. (2022). Antimicrobial Resistance Surveillance Reference Laboratory,
- 772 Annual Report. https://arsp.com.ph
- 773 Gajdács, M. (2020). Carbapenem-resistant but cephalosporin-susceptible Pseudomonas
- aeruginosa in urinary tract infections: Opportunity for colistin sparing. *Antibiotics*, *9*(4).
- 775 https://doi.org/10.3390/antibiotics9040153
- Gashaw, M., Gudina, E. K., Ali, S., Gabriele, L., Seeholzer, T., Alemu, B., Froeschl, G., Kroidl, A., &
- 777 Wieser, A. (2024). Molecular characterization of carbapenem-resistance in Gram-negative
- isolates obtained from clinical samples at Jimma Medical Center, Ethiopia. Frontiers in
- 779 *Microbiology*, *15*. https://doi.org/10.3389/fmicb.2024.1336387
- Gill, C. M., Aktaþ, E., Alfouzan, W., Bourassa, L., Brink, A., Burnham, C. A. D., Canton, R., Carmeli,
- 781 Y., Falcone, M., Kiffer, C., Marchese, A., Martinez, O., Pournaras, S., Satlin, M., Seifert, H.,

- 782 Thabit, A. K., Thomson, K. S., Villegas, M. V., & Nicolau, D. P. (2021). The ERACE-PA Global
- 783 Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity
- 784 against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa. *European*
- 785 Journal of Clinical Microbiology and Infectious Diseases, 40(12), 2533–2541.
- 786 https://doi.org/10.1007/s10096-021-04308-0
- 787 Guerrero-Araya, E., Muñoz, M., Rodríguez, C., & Paredes-Sabja, D. (2021). FastMLST: A Multi-core
- 788 Tool for Multilocus Sequence Typing of Draft Genome Assemblies. *Bioinformatics and Biology*
- 789 Insights, 15. https://doi.org/10.1177/11779322211059238
- Guo, X., Chen, R., Wang, Q., Li, C., Ge, H., Qiao, J., & Li, Y. (2022). Global prevalence, characteristics,
- and future prospects of IncX3 plasmids: A review. In *Frontiers in Microbiology* (Vol. 13).
 Frontiers Media S.A. https://doi.org/10.3389/fmicb.2022.979558
- Halat, D. H., & Moubareck, C. A. (2022). The Intriguing Carbapenemases of Pseudomonas
 aeruginosa: Current Status, Genetic Profile, and Global Epidemiology. In YALE JOURNAL OF
- 795 BIOLOGY AND MEDICINE (Vol. 95).
- 796 Hong, D. J., Bae, I. K., Jang, I. H., Jeong, S. H., Kang, H. K., & Lee, K. (2015). Epidemiology and
- characteristics of metallo-ß-lactamase-producing Pseudomonas aeruginosa. *Infection and Chemotherapy*, 47(2), 81–97. https://doi.org/10.3947/ic.2015.47.2.81
- Horcajada, J. P., Montero, M., Oliver, A., Sorlí, L., Luque, S., Gómez-Zorrilla, S., Benito, N., & Grau,
- S. (2019). Epidemiology and treatment of multidrug-resistant and extensively drug-resistant
- 801 Pseudomonas aeruginosa infections. *Clinical Microbiology Reviews*, 32(4).
- 802 https://doi.org/10.1128/CMR.00031-19

- 803 Hu, Y., Peng, W., Wu, Y., Li, H., Wang, Q., Yi, H., Zhang, R., Shao, B., & Zhu, K. (2021). A Potential
- High-Risk Clone of Pseudomonas aeruginosa ST463. Frontiers in Microbiology, 12.
 https://doi.org/10.3389/fmicb.2021.670202
- Jolley, K. A., Bray, J. E., & Maiden, M. C. J. (2018). Open-access bacterial population genomics:
- 807 BIGSdb software, the PubMLST.org website and their applications. *Wellcome Open Research*,
- 808 3. https://doi.org/10.12688/wellcomeopenres.14826.1
- Jolley, K. A., & Maiden, M. C. J. (2010). BIGSdb: Scalable analysis of bacterial genome variation at
- the population level. BMC Bioinformatics, 11(1), 595. https://doi.org/10.1186/1471-2105-
- 811 11-595
- Karlowsky, J. A., Kazmierczak, K. M., Bouchillon, S. K., De Jonge, B. L. M., Stone, G. G., & Sahm, D.
- 813 F. (2018). In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of
- 814 Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results
- 815 from the INFORM Global Surveillance Program, 2012 to 2015.
 816 https://journals.asm.org/journal/aac
- 817 Kocsis, B., Gulyás, D., & Szabó, D. (2021). Diversity and distribution of resistance markers in
- pseudomonas aeruginosa international high-risk clones. *Microorganisms*, 9(2), 1–14.
- https://doi.org/10.3390/microorganisms9020359
- Leungtongkam, U., Thummeepak, R., Tasanapak, K., & Sitthisak, S. (2018). Acquisition and transfer
 of antibiotic resistance genes in association with conjugative plasmid or class 1 integrons of
 Acinetobacter baumannii. *PLoS ONE*, *13*(12), 1–12.
- 823 https://doi.org/10.1371/journal.pone.0208468

- Li, H., Luo, Y. F., Williams, B. J., Blackwell, T. S., & Xie, C. M. (2012). Structure and function of OprD
- 825 protein in Pseudomonas aeruginosa: From antibiotic resistance to novel therapies. In
- 826 International Journal of Medical Microbiology (Vol. 302, Issue 2, pp. 63–68).
- 827 https://doi.org/10.1016/j.ijmm.2011.10.001
- Liakopoulos, A., Van Der Goot, J., Bossers, A., Betts, J., Brouwer, M. S. M., Kant, A., Smith, H.,
- 829 Ceccarelli, D., & Mevius, D. (2018). Genomic and functional characterisation of IncX3
- plasmids encoding bla SHV-12 in Escherichia coli from human and animal origin. *Scientific*
- 831 *Reports*, 8(1). https://doi.org/10.1038/s41598-018-26073-5
- Liu, J., Shen, Q., & Bao, H. (2022). Comparison of seven SNP calling pipelines for the next-
- generation sequencing data of chickens. *PLoS ONE*, *17*(1 January).
 https://doi.org/10.1371/journal.pone.0262574
- Llaca-Díaz, J. M., Mendoza-Olazarán, S., Camacho-Ortiz, A., Flores, S., & Garza-González, E. (2013).
- 836 One-year surveillance of eskape pathogens in an intensive care unit of monterrey, Mexico.

837 *Chemotherapy*, *58*(6), 475–481. https://doi.org/10.1159/000346352

- 838 Manohar, P., Leptihn, S., Lopes, B. S., & Nachimuthu, R. (2021). Dissemination of carbapenem
- resistance and plasmids encoding carbapenemases in Gram-negative bacteria isolated in
- 840 India. *JAC-Antimicrobial Resistance*, *3*(1). https://doi.org/10.1093/jacamr/dlab015
- Minh, B. Q., Schmidt, H. A., Chernomor, O., Schrempf, D., Woodhams, M. D., Von Haeseler, A.,
- Lanfear, R., & Teeling, E. (2020). IQ-TREE 2: New Models and Efficient Methods for
- Phylogenetic Inference in the Genomic Era. *Molecular Biology and Evolution*, 37(5), 1530–
- 844 1534. https://doi.org/10.1093/molbev/msaa015

845	Murray, C. J., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C.,
846	Bisignano, C., Rao, P., Wool, E., Johnson, S. C., Browne, A. J., Chipeta, M. G., Fell, F., Hackett,
847	S., Haines-Woodhouse, G., Kashef Hamadani, B. H., Kumaran, E. A. P., McManigal, B.,
848	Naghavi, M. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic
849	analysis. The Lancet, 399(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-
850	0
851	Nieto-Saucedo, J. R., López-Jacome, L. E., Franco-Cendejas, R., Colín-Castro, C. A., Hernández-
852	Duran, M., Rivera-Garay, L. R., Zamarripa-Martinez, K. S., & Mosqueda-Gómez, J. L. (2023).
853	Carbapenem-Resistant Gram-Negative Bacilli Characterization in a Tertiary Care Center from
854	El Bajio, Mexico. Antibiotics, 12(8). https://doi.org/10.3390/antibiotics12081295
855	Nordmann, P., & Poirel, L. (2019). Epidemiology and Diagnostics of Carbapenem Resistance in
856	Gram-negative Bacteria. Clinical Infectious Diseases, 69(Suppl 7), S521–S528.
857	https://doi.org/10.1093/cid/ciz824
858	Oliver, A., Mulet, X., López-Causapé, C., & Juan, C. (2015). The increasing threat of Pseudomonas
859	aeruginosa high-risk clones. In Drug Resistance Updates (Vols. 21–22, pp. 41–59). Churchill
860	Livingstone. https://doi.org/10.1016/j.drup.2015.08.002
861	Partridge, S. R., Kwong, S. M., Firth, N., & Jensen, S. O. (2018). Mobile Genetic Elements Associated
862	with Antimicrobial Resistance. Clinical Microbiology. https://doi.org/10
863	Pedersen, B. S., & Quinlan, A. R. (2018). Mosdepth: Quick coverage calculation for genomes and
864	exomes. <i>Bioinformatics, 34</i> (5), 867–868. https://doi.org/10.1093/bioinformatics/btx699
865	Pedroso, M. M., Waite, D. W., Melse, O., Wilson, L., Mitić, N., McGeary, R. P., Antes, I., Guddat, L.
866	W., Hugenholtz, P., & Schenk, G. (2020). Broad spectrum antibiotic-degrading metallo-β-

- 867 lactamases are phylogenetically diverse. In *Protein and Cell* (Vol. 11, Issue 8, pp. 613–617).
- 868 Higher Education Press. https://doi.org/10.1007/s13238-020-00736-4
- Pollini, S., Maradei, S., Pecile, P., Olivo, G., Luzzaro, F., Docquier, J. D., & Rossolini, G. M. (2013).
- FIM-1, a new acquired metallo- β -lactamase from a Pseudomonas aeruginosa clinical isolate
- 871 from Italy. *Antimicrobial Agents and Chemotherapy*. https://doi.org/10.1128/AAC.01953-12
- Queenan, A. M., & Bush, K. (2007). Carbapenemases: The versatile β-lactamases. In *Clinical Microbiology Reviews*. https://doi.org/10.1128/CMR.00001-07
- 874 Raman, G., Avendano, E. E., Chan, J., Merchant, S., & Puzniak, L. (2018). Risk factors for
- hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa
 infections: A systematic review and meta-analysis. *Antimicrobial Resistance and Infection Control, 7*(1). https://doi.org/10.1186/s13756-018-0370-9
- 878 Ramirez, M. S., Traglia, G. M., Lin, D. L., Tran, T., & Tolmasky, M. E. (2014). Plasmid-Mediated
- 879 Antibiotic Resistance and Virulence in Gram-Negatives: the Klebsiella pneumoniae Paradigm.

880 *Microbiology Spectrum*, 2(5), 1–15. https://doi.org/10.1128/microbiolspec.plas-0016-2013

Reuland, E. A., Halaby, T., Hays, J. P., De Jongh, D. M. C., Snetselaar, H. D. R., Van Keulen, M., Elders,

- P. J. M., Savelkoul, P. H. M., Vandenbroucke-Grauls, C. M. J. E., & Al Naiemi, N. (2015).
- Plasmid-mediated AmpC: Prevalence in community-acquired isolates in Amsterdam, the Netherlands, and risk factors for carriage. *PLoS ONE*, *10*(1), 1–9. https://doi.org/10.1371/journal.pone.0113033
- Reyes, J., Komarow, L., Chen, L., Ge, L., Hanson, B. M., Cober, E., Herc, E., Alenazi, T., Kaye, K. S.,
 Garcia-Diaz, J., Li, L., Kanj, S. S., Liu, Z., Oñate, J. M., Salata, R. A., Marimuthu, K., Gao, H.,
- Zong, Z., Valderrama-Beltrán, S. L., ... Satlin, M. (2023). Global epidemiology and clinical

889	outcomes	of	carbapenem-resistant	Pseudomonas	aeruginosa	and	associated
890	carbapenen	nases	(POP): a prospective co	hort study. <i>The L</i>	ancet Microbe	e, 4(3),	e159–e170.
891	https://doi.o	org/1	.0.1016/S2666-5247(22)0	00329-9			
892	Rice, L. B. (200	8). F	ederal funding for the	study of antimic	crobial resistar	nce in	nosocomial
893	pathogens:	No E	SKAPE. In <i>Journal of Infe</i> d	ctious Diseases (\	/ol. 197, Issue	8, pp. 1	1079–1081).
894	https://doi.	org/1	0.1086/533452				

- Sahuquillo-Arce, J. M. (2015). Carbapenemases: A worldwide threat to antimicrobial therapy.
 World Journal of Pharmacology, 4(1), 75. https://doi.org/10.5497/wjp.v4.i1.75
- 897 Sánchez-Busó, L., Yeats, C. A., Taylor, B., Goater, R. J., Underwood, A., Abudahab, K., Argimón, S.,
- Ma, K. C., Mortimer, T. D., Golparian, D., Cole, M. J., Grad, Y. H., Martin, I., Raphael, B. H.,
- 899 Shafer, W. M., Town, K., Wi, T., Harris, S. R., Unemo, M., & Aanensen, D. M. (2021). A
- 900 community-driven resource for genomic epidemiology and antimicrobial resistance
- 901 prediction of Neisseria gonorrhoeae at Pathogenwatch. *Genome Medicine*, 13(1).
- 902 https://doi.org/10.1186/s13073-021-00858-2
- Sapula, S. A., Amsalu, A., Whittall, J. J., Hart, B. J., Siderius, N. L., Nguyen, L., Gerber, C., Turnidge,
- J., & Venter, H. (2023). The scope of antimicrobial resistance in residential aged care facilities
- 905 determined through analysis of Escherichia coli and the total wastewater resistome .
- 906 *Microbiology Spectrum*, 11(6). https://doi.org/10.1128/spectrum.00731-23
- 907 Sawa, T., Kooguchi, K., & Moriyama, K. (2020). Molecular diversity of extended-spectrum β-
- 908 lactamases and carbapenemases, and antimicrobial resistance. In *Journal of Intensive Care*
- 909 (Vol. 8, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s40560-020-0429-6

Schäfer, E., Malecki, M., Tellez-Castillo, C. J., Pfennigwerth, N., Marlinghaus, L., Higgins, P. G., 910 911 Mattner, F., & Wendel, A. F. (2019). Molecular surveillance of carbapenemase-producing Pseudomonas aeruginosa at three medical centres in Cologne, Germany. Antimicrobial 912 *Resistance and Infection Control*, 8(1). https://doi.org/10.1186/s13756-019-0665-5 913 914 Seah, Y. M., Stewart, M. K., Hoogestraat, D., Ryder, M., Cookson, B. T., Salipante, S. J., & Hoffman, N. G. (2023). In Silico Evaluation of Variant Calling Methods for Bacterial Whole-Genome 915 916 Sequencing Assays. Journal of Clinical Microbiology, 61(8). 917 https://doi.org/10.1128/jcm.01842-22 Shariati, A., Azimi, T., Ardebili, A., Chirani, A. S., Bahramian, A., Pormohammad, A., Sadredinamin, 918 M., Erfanimanesh, S., Bostanghadiri, N., Shams, S., & Hashemi, A. (2018). Insertional 919 920 inactivation of oprD in carbapenem-resistant Pseudomonas aeruginosa strains isolated from burn patients in Tehran, Iran. New Microbes and New Infections, 21, 75-80. 921 922 https://doi.org/10.1016/j.nmni.2017.10.013 923 Shu, J. C., Kuo, A. J., Su, L. H., Liu, T. P., Lee, M. H., Su, I. N., & Wu, T. L. (2017). Development of carbapenem resistance in Pseudomonas aeruginosa is associated with OprD polymorphisms, 924 particularly the amino acid substitution at codon 170. Journal of Antimicrobial 925 926 *Chemotherapy*, 72(9), 2489–2495. https://doi.org/10.1093/jac/dkx158 Sid Ahmed, M. A., Khan, F. A., Hadi, H. A., Skariah, S., Sultan, A. A., Salam, A., Al Khal, A. L., 927 928 Söderquist, B., Ibrahim, E. B., Omrani, A. S., & Jass, J. (2022). Association of blaVIM-2, blaPDC-929 35, blaOXA-10, blaOXA-488 and blaVEB-9 β-Lactamase Genes with Resistance to Ceftazidime- Avibactam and Ceftolozane-Tazobactam in Multidrug-Resistant Pseudomonas 930 aeruginosa. Antibiotics, 11(2). https://doi.org/10.3390/antibiotics11020130 931

- 932 Siguier, P., Gourbeyre, E., Varani, A., Ton-Hoang, B., & Chandler, M. (2015). Everyman's Guide to
- Bacterial Insertion Sequences. Microbiology Spectrum, 3(2).
 https://doi.org/10.1128/microbiolspec.mdna3-0030-2014
- Siguier, P., Perochon, J., Lestrade, L., Mahillon, J., & Chandler, M. (2006). ISfinder: the reference
 centre for bacterial insertion sequences. *Nucleic Acids Research*, *34*(Database issue).
- 937 https://doi.org/10.1093/nar/gkj014
- 938 Sihombing, B., Bhatia, R., Srivastava, R., Aditama, T. Y., Laxminarayan, R., & Rijal, S. (2023).
- 939 Response to antimicrobial resistance in South-East Region. In The Lancet Regional Health -
- 940
 Southeast
 Asia
 (Vol.
 18,
 Issue
 100306).
 Elsevier
 Ltd.

 941
 https://doi.org/10.1016/j.lansea.2023.100303
- 942 Stover, C. K., Pham², X. Q., Erwin, A. L., Mizoguchi, S. D., Warrener, P., Hickey, M. J., Brinkman³, F.
- 943 S. L., Hufnagle, W. O., Kowalik, D. J., Lagrou, M., Garber, R. L., Goltry, L., Tolentino, E.,
- 944 Westbrock-Wadman, S., Yuan, Y., Brody, L. L., Coulter, S. N., Folger, K. R., Kas², A., ... Olson²,
- 945 M. V. (2000). Complete genome sequence of Pseudomonas aeruginosa PAO1, an 946 opportunistic pathogen. *Nature*, *406*. www.nature.com
- Suzuki, Y., Nazareno, P. J., Nakano, R., Mondoy, M., Nakano, A., Bugayong, M. P., Bilar, J., Perez, M.,
 Medina, E. J., Saito-Obata, M., Saito, M., Nakashima, K., Oshitani, H., & Yano, H. (2019).
 Environmental Presence and Genetic Characteristics of Carbapenemase-Producing
 Enterobacteriaceae from Hospital Sewage and River Water in the Philippines. *Applied and Environmental Microbiology*. https://doi.org/10
- Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C.,
 Kahlmeter, G., Kluytmans, J., Carmeli, Y., Ouellette, M., Outterson, K., Patel, J., Cavaleri, M.,

- 954 Cox, E. M., Houchens, C. R., Grayson, M. L., Hansen, P., Singh, N., ... Zorzet, A. (2018).
- 955 Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-
- 956 resistant bacteria and tuberculosis. *The Lancet Infectious Diseases*, 18(3), 318–327.
- 957 https://doi.org/10.1016/S1473-3099(17)30753-3
- Tacconelli, E., Carrara, E., Savoldi, A., Kattula, D., & Burkert, F. (2017). *Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics*. http://www.cdc.gov/drugresistance/threat-report-2013/
- 961 Teixeira, M., Pillay, S., Urhan, A., & Abeel, T. (2023). SHIP: identifying antimicrobial resistance gene
- 962 transfer between plasmids. *Bioinformatics, 39*(10).
 963 https://doi.org/10.1093/bioinformatics/btad612
- Tönnies, H., Prior, K., Harmsen, D., & Mellmann, A. (2021). Establishment and evaluation of a core
 genome multilocus sequence typing scheme for whole-genome sequence-based typing of
- 966 pseudomonas aeruginosa. *Journal of Clinical Microbiology*, 59(3).
- 967 https://doi.org/10.1128/JCM.01987-20
- 968 US Department of Health and Human Services; CDC. (2019). Carbapenem-Resistant
 969 Acinetobacter. *Center for Disease Control and Prevention*, 17–23.
 970 https://doi.org/10.5848/dos.978-1-909293-20-5_3
- Venkataramana, G. P., Lalitha, A. K. V., Mariappan, S., & Sekar, U. (2022). Plasmid-Mediated
 Fluoroquinolone Resistance in Pseudomonas aeruginosa and Acinetobacter baumannii. *Journal of Laboratory Physicians*, *14*(03), 271–277. https://doi.org/10.1055/s-0042-1742636
 Wang, M. G., Liu, Z. Y., Liao, X. P., Sun, R. Y., Li, R. B., Liu, Y., Fang, L. X., Sun, J., Liu, Y. H., & Zhang,
 R. M. (2021). Retrospective data insight into the global distribution of carbapenemase-

- 976 producing pseudomonas aeruginosa. Antibiotics, 10(5).
- 977 https://doi.org/10.3390/antibiotics10050548
- 978 Willyard, C. (2017). The drug-resistant bacteria that pose the greatest health threats. Nature,
- 979 *543*(15).
- 980 Wood, D. E., Lu, J., & Langmead, B. (2019). Improved metagenomic analysis with Kraken 2. *BioRxiv*.
- 981 https://doi.org/10.1101/762302
- 982 Yoon, E. J., & Jeong, S. H. (2021). Mobile Carbapenemase Genes in Pseudomonas aeruginosa. In
- 983 Frontiers in Microbiology (Vol. 12). Frontiers Media S.A.
- 984 https://doi.org/10.3389/fmicb.2021.614058
- 285 Zhao, W.-H., & Hu, Z.-Q. (2015). Acquired metallo-β-lactamases and their genetic association with
- 986 class 1 integrons and ISCR elements in Gram-negative bacteria. *Future Microbiol*, *5*, 873–887.
- 987 https://doi.org/10.2217/FMB.15.18
- 988

989 ONLINE REFERENCES

- 990 <u>https://github.com/tseemANn/snippy</u>
- 991 <u>https://github.com/abulenciamiguel/EpiTomas</u>
- 992 https://cgps.gitbook.io/pathogenwatch/technical-descriptions/typing-methods/mlst